U.S. patent application number 10/766735 was filed with the patent office on 2004-12-30 for methods and compositions for the treatment of gastrointestinal disorders.
Invention is credited to Currie, Mark G., Mahajan-Miklos, Shalina.
Application Number | 20040266989 10/766735 |
Document ID | / |
Family ID | 32854294 |
Filed Date | 2004-12-30 |
United States Patent
Application |
20040266989 |
Kind Code |
A1 |
Currie, Mark G. ; et
al. |
December 30, 2004 |
Methods and compositions for the treatment of gastrointestinal
disorders
Abstract
The present invention features compositions and related methods
for treating IBS and other gastrointestinal disorders and
conditions (e.g., gastrointestinal motility disorders, functional
gastrointestinal disorders, gastroesophageal reflux disease (GERD),
Crohn's disease, ulcerative colitis, Inflammatory bowel disease,
functional heartburn, dyspepsia (including functional dyspepsia or
nonulcer dyspepsia), gastroparesis, chronic intestinal
pseudo-obstruction (or colonic pseudo-obstruction), and disorders
and conditions associated with constipation, e.g., constipation
associated with use of opiate pain killers, post-surgical
constipation, and constipation associated with neuropathic
disorders as well as other conditions and disorders using peptides
and other agents that activate the guanylate cyclase C (GC--C)
receptor.
Inventors: |
Currie, Mark G.; (Sterling,
MA) ; Mahajan-Miklos, Shalina; (Needham, MA) |
Correspondence
Address: |
FISH & RICHARDSON PC
225 FRANKLIN ST
BOSTON
MA
02110
US
|
Family ID: |
32854294 |
Appl. No.: |
10/766735 |
Filed: |
January 28, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60443098 |
Jan 28, 2003 |
|
|
|
60471288 |
May 15, 2003 |
|
|
|
60519460 |
Nov 12, 2003 |
|
|
|
Current U.S.
Class: |
530/326 |
Current CPC
Class: |
A61P 1/12 20180101; A61P
9/04 20180101; A61P 3/12 20180101; A61P 25/18 20180101; A61P 1/16
20180101; A61P 11/00 20180101; A61P 25/24 20180101; A61P 1/04
20180101; A61P 25/22 20180101; A61P 1/10 20180101; A61P 1/14
20180101; A61P 29/00 20180101; A61P 35/04 20180101; A61P 5/50
20180101; A61P 11/06 20180101; A61P 43/00 20180101; A61K 38/00
20130101; A61P 35/02 20180101; A61P 3/04 20180101; A61P 15/10
20180101; A61P 25/20 20180101; A61P 3/10 20180101; A61P 27/16
20180101; A61P 3/00 20180101; A61P 7/10 20180101; C07K 14/245
20130101; A61P 13/00 20180101; A61P 25/04 20180101; A61P 9/10
20180101; A61P 13/08 20180101; A61P 13/12 20180101; C07K 7/08
20130101; A61P 25/00 20180101; A61P 25/28 20180101; A61P 35/00
20180101; A61P 1/08 20180101; A61P 1/00 20180101; A61P 9/00
20180101; A61P 1/18 20180101 |
Class at
Publication: |
530/326 |
International
Class: |
C07K 007/08 |
Claims
1. A purified peptide comprising the amino acid sequence (I):
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4Xaa.sub.5Cys.sub.6Cys.sub.7Xaa.sub.8X-
aa.sub.9Cys.sub.10Cys.sub.11Xaa.sub.12Xaa.sub.13Xaa.sub.14Cys.sub.15Xaa.su-
b.16Xaa.sub.17Cys.sub.18Xaa.sub.1Xaa.sub.20Xaa.sub.21 (SEQ ID
NO:119) wherein: Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4Xaa.sub.5 is
Asn Ser Ser Asn Tyr (SEQ ID NO:121 )or is missing or
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4 is missing.
2. The purified peptide of claim 1 wherein Xaa.sub.5 is Asn, Trp,
Tyr, Asp, or Phe.
3. The purified peptide of claim 1 wherein Xaa.sub.5 is Thr or
Ile.
4. The purified peptide of claim 1 wherein Xaa.sub.5 is Tyr, Asp or
Trp.
5. The purified peptide of claim 1 wherein Xaa.sub.8 is Glu, Asp,
Gln, Gly or Pro.
6. The purified peptide of claim 1 wherein Xaa.sub.9 is Leu, Ile,
Val, Ala, Lys, Arg, Trp, Tyr or Phe.
7. The purified peptide of claim 1 wherein Xaa.sub.9 is Leu, Ile,
Val, Lys, Arg, Trp, Tyr or Phe.
8. The purified peptide of claim 1 wherein Xaa.sub.12 is Asn, Tyr,
Asp or Ala.
9. The purified peptide of claim 1 wherein Xaa.sub.13 is Ala, Pro
or Gly.
10. The purified peptide of claim 1 wherein Xaa.sub.14 is Ala, Leu,
Ser, Gly, Val, Glu, Gln, Ile, Leu, Lys, Arg, or Asp.
11. The purified peptide of claim 1 wherein Xaa.sub.16 is Thr, Ala,
Asn, Lys, Arg, Trp.
12. The purified peptide of claim 1 wherein Xaa.sub.17 is Gly, Pro
or Ala.
13. The purified peptide of claim 1 wherein Xaa.sub.19 is Trp, Tyr,
Phe, Asn or Leu.
14. The purified peptide of claim 1 wherein Xaa.sub.19 is Lys or
Arg.
15. The purified peptide of claim 1 wherein Xaa.sub.20 Xaa.sub.21
is AspPhe or Xaa.sub.20 is Asn or Glu and Xaa.sub.21 is
missing.
16. A purified peptide comprising the amino acid sequence:
5 Asn Ser Ser Asn Tyr Cys Cys (SEQ ID NO:[[---]]28; Glu Tyr Cys Cys
Asn Pro Ala MD-915) Cys Thr Gly Cys Tyr.
17. A purified peptide comprising the amino acid sequence:
6 Cys Cys Glu Tyr Cys Cys Asn (SEQ ID NO:[[--]]31; Pro Ala Cys Thr
Gly Cys Tyr. MD-1100)
18. A purified peptide consisting of the amino acid sequence:
7 Asn Ser Ser Asn Tyr Cys Cys (SEQ ID NO:[[--]]28 Glu Tyr Cys Cys
Asn Pro Ala MD-915) Cys Thr Gly Cys Tyr.
19. A purified peptide consisting of the amino acid sequence:
8 Cys Cys Glu Tyr Cys Cys Asn (SEQ ID NO:[[--]]31; Pro Ala Cys Thr
Gly Cys Tyr. MD-1100)
20. A method for treating a gastrointestinal disorder in a patient
comprising administering a purified peptide comprising the amino
acid sequence:
9 Asn Ser Ser Asn Tyr Cys Cys [SEQ ID NO:[[--]]26; Glu Leu Cys Cys
Asn Pro Ala MM-416776) Cys Thr Gly Cys Tyr.
21. A method for treating a gastrointestinal disorder in a patient
comprising administering a purified peptide comprising the amino
acid sequence:
10 Asn Ser Ser Asn Tyr Cys Cys (SEQ ID NO:[[---]]28; Glu Tyr Cys
Cys Asn Pro Ala MD-915) Cys Thr Gly Cys Tyr.
22. A method for treating a gastrointestinal disorder in a patient
comprising administering a purified peptide comprising the amino
acid sequence:
11 Cys Cys Glu Leu Cys Cys Asn (SEQ ID NO:[[--]]29; Pro Ala Cys Thr
Gly Cys Tyr MM416774)
23. A method for treating a gastrointestinal disorder in a patient
comprising administering a purified peptide comprising the amino
acid sequence:
12 Cys Cys Glu Tyr Cys Cys Asn (SEQ ID NO:[[--]]29; Pro Ala Cys Thr
Gly Cys Tyr. MD-1100)
24. A purified polypeptide comprising an amino acid sequence of any
of:
13 Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Trp
Gly Cys Tyr; (SEQ ID NO:[[--]]27) Cys Cys Glu Leu Cys Cys Asn Pro
Ala Cys Trp Gly Cys Tyr; (SEQ ID NO:[---]30) Asn Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:[[---]32) Asn
Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Trp Gly Cys Tyr; (SEQ ID
NO:[---]33) Asn Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr; (SEQ ID NO:[---]34) Asn Cys Cys Glu Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr; (SEQ ID NO:[---]35) Asn Cys Cys Glu Trp Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:[---]36) Asn Cys
Cys Glu Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID
NO:[---]37) Asn Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr; (SEQ ID NO:[---]38) Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp (SEQ ID NO:[---]39) Phe;
Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Trp Gly
Cys Tyr Asp (SEQ ID NO:[---]40) Phe; Asn Ser Ser Asn Tyr Cys Cys
Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp (SEQ ID
NO:[---]41) Phe; Asn Ser Ser Asn Tyr Cys Cys Glu Tyr Cys Cys Asn
Pro Ala Cys Thr Gly Cys Tyr Asp (SEQ ID NO:[---]42) Phe; Asn Ser
Ser Asn Tyr Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
Asp (SEQ ID NO:[---]43) Phe; Asn Ser Ser Asn Tyr Cys Cys Glu Arg
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp (SEQ ID NO:[---]44)
Phe; Asn Ser Ser Asn Tyr Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys
Thr Gly Cys Tyr Asp (SEQ ID NO:[---]45) Phe; Cys Cys Glu Leu Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe; (SEQ ID NO:[---]46)
Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Trp Gly Cys Tyr Asp Phe;
(SEQ ID NO:[---]47) Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr Asp Phe; (SEQ ID NO:[---]48) Cys Cys Glu Tyr Cys Cys Asn
Pro Ala Cys Thr Gly Cys Tyr Asp Phe; (SEQ ID NO:[---]49) Cys Cys
Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe; (SEQ ID
NO:[---]50) Cys Cys Glu Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
Asp Phe; (SEQ ID NO:[---]51) Cys Cys Glu Lys Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr Asp Phe; (SEQ ID NO:[--]52) Asn Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe; (SEQ ID NO:[--])53
Asn Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Trp Gly Cys Tyr Asp
Phe; (SEQ ID NO: [---])54 Asn Cys Cys Glu Phe Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr Asp Phe; (SEQ ID NO:[---]55) Asn Cys Cys Glu
Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe; (SEQ ID
NO:[---]56) Asn Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr Asp Phe; (SEQ ID NO:[---]57) Asn Cys Cys Glu Arg Cys Cys Asn
Pro Ala Cys Thr Gly Cys Tyr Asp Phe; (SEQ ID NO:[---]58) Asn Cys
Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe; (SEQ
ID NO:[---]59) Gln Ser Ser Asn Tyr Cys Cys Glu Tyr Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:[---]67) Asn Thr Ser Asn Tyr
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID
NO:[---]68) Asn Leu Ser Asn Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr; (SEQ ID NO:[---]69) Asn Ile Ser Asn Tyr Cys
Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID
NO:[---]70) Asn Ser Ser Gln Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr; (SEQ ID NO:[---]71) Ser Ser Asn Tyr Cys Cys
Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID
NO:[---]72) Gln Ser Ser Gln Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr; (SEQ ID NO:[---]73) Ser Ser Gln Tyr Cys Cys
Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID
NO:[---]74) Asn Ser Ser Asn Tyr Cys Cys Glu Ala Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr; (SEQ ID NO:75) Asn Ser Ser Asn Tyr Cys Cys Glu
Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:76) Asn Ser
Ser Asn Tyr Cys Cys Glu Asn Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr; (SEQ ID NO:77) Asn Ser Ser Asn Tyr Cys Cys Glu Asp Cys Cys Asn
Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:78) Asn Ser Ser Asn Tyr Cys
Cys Glu Cys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:79)
Asn Ser Ser Asn Tyr Cys Cys Glu Gln Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr; (SEQ ID NO:80) Asn Ser Ser Asn Tyr Cys Cys Glu Glu Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:81) Asn Ser Ser Asn Tyr
Cys Cys Glu Gly Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID
NO:82) Asn Ser Ser Asn Tyr Cys Cys Glu His Cys Cys Asn Pro Ala Cys
Thr Gly Cys Tyr; (SEQ ID NO:83) Asn Ser Ser Asn Tyr Cys Cys Glu Ile
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:84) Asn Ser Ser
Asn Tyr Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:85) Asn Ser Ser Asn Tyr Cys Cys Glu Met Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:86) Asn Ser Ser Asn Tyr Cys Cys
Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:87) Asn
Ser Ser Asn Tyr Cys Cys Glu Pro Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr; (SEQ ID NO:88) Asn Ser Ser Asn Tyr Cys Cys Glu Ser Cys Cys Asn
Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:89) Asn Ser Ser Asn Tyr Cys
Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:90)
Asn Ser Ser Asn Tyr Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr; (SEQ ID NO:91) Asn Ser Ser Asn Tyr Cys Cys Glu Val Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:92) Cys Cys Glu Ala Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:93) Cys Cys Glu Arg
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:94) Cys Cys Glu
Asn Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:95) Cys Cys
Glu Asp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:96) Cys
Cys Glu Cys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:97)
Cys Cys Glu Gln Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID
NO:98) Cys Cys Glu Glu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:99) Cys Cys Glu Gly Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr; (SEQ ID NO:100) Cys Cys Glu His Cys Cys Asn Pro Ala Cys Thr
Gly Cys Tyr; (SEQ ID NO:101) Cys Cys Glu Ile Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr; (SEQ ID NO:102) Cys Cys Glu Lys Cys Cys Asn
Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:103) Cys Cys Glu Met Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:104) Cys Cys Glu
Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:105) Cys
Cys Glu Pro Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID
NO:106) Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr;
(SEQ ID NO:107) Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr; (SEQ ID NO:108) Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr
Gly Cys Tyr; (SEQ ID NO:109) Cys Cys Glu Val Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr; (SEQ ID NO:110) Asn Ser Ser Asn Tyr Cys Cys
Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr; (SEQ ID NO:[--]26;
and MM-416776) Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr. (SEQ ID NO:[--]29; MM416774)
25. A method for treating a gastrointestinal disorder in a patient
comprising administering the peptide of claim 1.
26. A method for treating a gastrointestinal disorder in a patient
comprising administering the peptide of claim 24.
27. The method of any of claims 20-26 wherein the gastrointestinal
disorder is a gastrointestinal motility disorder.
28. The method of any of claims 20-26 wherein the gastrointestinal
disorder is selected from the group consisting of a
gastrointestinal motility disorder, irritable bowel syndrome,
chronic constipation, a functional gastrointestinal disorder,
gastroesophageal reflux disease, functional heartburn, dyspepsia,
functional dyspepsia, nonulcer dyspepsia, gastroparesis, chronic
intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's
disease, ulcerative colitis, and inflammatory bowel disease.
29. A method for treating obesity comprising administering the
peptide of any of claims 1, 16-19, and 24.
30. A method for treating congestive heart failure comprising
administering the peptide of any of claims 1, 16-19, and 24.
31. A method for treating benign prostatic hyperplasia comprising
administering the peptide of any of claims 1, 16-19, and 24.
32. The purified peptide of any of claims 1, 16, 17, and 24 wherein
the polypeptide comprises the amino acid sequence DF; QHNPR (SEQ ID
NO:111); VQHNPR (SEQ ID NO:112); VRQHNPR (SEQ ID NO:113); VRGQHNPR
(SEQ ID NO:114); VRGPQHNPR (SEQ ID NO:115); VRGPRQHNPR (SEQ ID
NO:116); VRGPRRQHNPR (SEQ ID NO:117); or RQHNPR (SEQ ID NO:118)
fused to its amino terminus or its caboxy terminus.
33. The purified peptide of any of claims 1, 16, 17, and 24 wherein
the purified polypeptide comprises the amino acid sequence of an
analgesic peptide selected from the group consisting of
endomorphin-1, endomorphin-2, nocistatin, dalargin, lupron, and
substance P fused to its amino terminus or its carboxy
terminus.
34. The purified peptide of any of claims 1, 16, 17, and 24 wherein
the polypeptide includes no more than 10 additional amino acids at
its amino terminus or carboxy terminus or both and wherein the
polypeptide is a guanylate cyclase receptor agonist.
35. The purified peptide of claim 1 wherein wherein: Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is missing; Xaa.sub.8 is
Glu; Xaa.sub.9 is Leu, Ile, Lys, Arg, Trp, Tyr or Phe; Xaa.sub.12
is Asn; Xaa.sub.13 is Pro; Xaa.sub.14 is Ala; Xaa.sub.16 is Thr,
Ala, Lys, Arg, Trp; Xaa.sub.17 is Gly; Xaa.sub.19 is Tyr or Leu;
and Xaa.sub.20 Xaa.sub.21 is AspPhe or is missing.
36. A method for treating a patient suffering from constipation,
the method comprising administering the polypeptide of any of
claims 1, 16-23 and 28.
37. A method for increasing the activity of an intestinal guanylate
cyclase (GC--C) receptor in a patient, the method comprising
administering the polypeptide of any of claims 1, 16-19 and 24.
38. A method for treating a gastrointestinal disorder in a patient
comprising administering a GC--C receptor agonist.
39. The method of claim 38 wherein the gastrointestinal disorder is
a gastrointestinal motility disorder.
40. The method of claim 38 wherein the gastrointestinal disorder is
selected from the group consisting of a gastrointestinal motility
disorder, irritable bowel syndrome, chronic constipation, a
functional gastrointestinal disorder, gastroesophageal reflux
disease, functional heartburn, dyspepsia, functional dyspepsia,
nonulcer dyspepsia, gastroparesis, chronic intestinal
pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease,
ulcerative colitis, and inflammatory bowel disease.
41. A method for treating obesity comprising administering a GC--C
receptor agonist.
42. A method for treating congestive heart failure comprising
administering a GC--C receptor agonist.
43. A method for treating benign prostatic hyperplasia comprising
administering a GC--C receptor agonist.
44. A method for treating visceral pain comprising administering a
GC--C receptor agonist.
45. A method for treating inflammation comprising administering a
GC--C receptor agonist.
46. A method for treating constipation comprising administering a
GC--C receptor agonist.
47. A method for treating visceral pain comprising administering
the polypeptide of any of claims 1, 16-19 and 24.
48. A method for treating inflammation comprising administering the
polypeptide of any of claims 1, 16-19 and 24.
49. A method for treating cystic fibrosis comprising administering
the polypeptide of any of claims 1, 16-19 and 24.
50. A method for treating cystic fibrosis comprising administering
a GC--C receptor agonist.
51. A pharmaceutical composition comprising the peptide of any of
claims 1, 16-19 and 24 and a pharmaceutically acceptable
carrier.
52. A pharmaceutical composition comprising the peptide of any of
claims 1, 16-19 and 24 surrounded by an enteric coating.
53. A controlled release pharmaceutical composition comprising the
peptide of any of claims 1, 16-19 and 24 and a biodegradable
polymeric matrix.
54. A pharmaceutical composition comprising the peptide of any of
claims 1, 16-19 and 24, an analgesic agent and a pharmaceutically
acceptable carrier.
55. A pharmaceutical composition comprising the peptide of any of
claims 1, 16-19 and 24, a phosphodiesterase inhibitor and a
pharmaceutically acceptable carrier.
56. A method for treating cancer, a respiratory disorder, a
neurological disorder, a disorder associated with fluid and sodium
retention, a disorder associated with carbonate imbalance, erectile
dysfunction, an insulin-related disorder, or an inner ear disorder,
the method comprising administering the peptide of any of claims 1,
16-19 and 24.
57. A method for treating cancer, a respiratory disorder, a
neurological disorder, a disorder associated with fluid and sodium
retention, a disorder associated with carbonate imbalance, erectile
dysfunction, an insulin-related disorder, or an inner ear disorder,
the method comprising administering a GC--C receptor agonist.
58. A method of producing the peptide of any of claims 16-19 and
24, comprising providing a cell harboring a nucleic acid molecule
encoding the polypeptide, culturing the cell under conditions in
which the peptide is expressed, and isolating the expressed
peptide.
59. A method of producing the peptide of any of claims 16-19 and
24, comprising chemically synthesizing the peptide and they
purifying the synthesized peptide.
60. A pharmaceutical composition comprising the peptide of any of
claims 1, 16-19 and 24 and a natriuretic peptide such as atrial
natriuretic peptide, brain natriuretic peptide, a C-type
natriuretic peptide, a diuretic, or an inhibitor of angiotensin
converting enzyme.
61. A pharmaceutical composition comprising the peptide of any of
claims 1, 16-19 and 24 and a 5-alpha reductase inhibitor or an
alpha adrenergic inhibitor.
62. A pharmaceutical composition comprising the peptide of any of
claims 1, 16-19 and 24 and gut hormone fragment peptide
YY.sub.3-36, glp-1 (glucagon-like peptide-1), exendin-4 (an
inhibitor of glp-1), sibutramine, phentermine, phendimetrazine,
benzphetamine hydrochloride (Didrex), orlistat (Xenical),
diethylpropion hydrochloride (Tenuate), fluoxetine (Prozac),
bupropion, ephedra, chromium, garcinia cambogia, benzocaine,
bladderwrack (focus vesiculosus), chitosan, nomame herba, galega
(Goat's Rue, French Lilac), conjugated linoleic acid, L-carnitine,
fiber (psyllium, plantago, guar fiber), caffeine,
dehydroepiandrosterone, germander (teucrium chamaedrys),
B-hydroxy-.beta.-methylbutyrate, or pyruvate.
63. A pharmaceutical composition comprising a GC--C receptor
agonist and a natriuretic peptide such as atrial natriuretic
peptide, brain natriuretic peptide, a C-type natriuretic peptide, a
diuretic, or an inhibitor of angiotensin converting enzyme.
64. A pharmaceutical composition comprising a GC--C receptor
agonist and a 5-alpha reductase inhibitor or an alpha adrenergic
inhibitor.
65. A pharmaceutical composition comprising a GC--C receptor
agonist and gut hormone fragment peptide YY.sub.3-36, glp-1
(glucagon-like peptide-1), exendin-4 (an inhibitor of glp-1),
sibutramine, phentermine, phendimetrazine, benzphetamine
hydrochloride (Didrex), orlistat (Xenical), diethylpropion
hydrochloride (Tenuate), fluoxetine (Prozac), bupropion, ephedra,
chromium, garcinia cambogia, benzocaine, bladderwrack (focus
vesiculosus), chitosan, nomame herba, galega (Goat's Rue, French
Lilac), conjugated linoleic acid, L-carnitine, fiber (psyllium,
plantago, guar fiber), caffeine, dehydroepiandrosterone, germander
(teucrium chamaedrys), B-hydroxy-,-methylbutyrate, or pyruvate.
66. A method for treating congestive heart failure comprising
administering the peptide of any of claims 1, 16-19 and 24 and a
natriuretic peptide such as atrial natriuretic peptide, brain
natriuretic peptide, a C-type natriuretic peptide, a diuretic, or
an inhibitor of angiotensin converting enzyme.
67. A method for treating benign prostatic hyperplasia comprising
administering the peptide of any of claims 1, 16-19 and 24 and a
5-alpha reductase inhibitor or an alpha adrenergic inhibitor.
68. A method for treating obesity comprising administering the
peptide of any of claims 1, 16-19 and 24 and gut hormone fragment
peptide YY.sub.3-36, glp-1 (glucagon-like peptide-1), exendin-4 (an
inhibitor of glp-1), sibutramine, phentermine, phendimetrazine,
benzphetamine hydrochloride (Didrex), orlistat (Xenical),
diethylpropion hydrochloride (Tenuate), fluoxetine (Prozac),
bupropion, ephedra, chromium, garcinia cambogia, benzocaine,
bladderwrack (focus vesiculosus), chitosan, nomame herba, galega
(Goat's Rue, French Lilac), conjugated linoleic acid, L-carnitine,
fiber (psyllium, plantago, guar fiber), caffeine,
dehydroepiandrosterone, germander (teucrium chamaedrys),
B-hydroxy-.beta.-methylbutyrate, or pyruvate.
69. A method for treating congestive heart failure comprising
administering a GC--C receptor agonist and a natriuretic peptide
such as atrial natriuretic peptide, brain natriuretic peptide, a
C-type natriuretic peptide, a diuretic, or an inhibitor of
angiotensin converting enzyme.
70. A method for treating benign prostatic hyperplasia comprising a
GC--C receptor agonist and a 5-alpha reductase inhibitor or an
alpha adrenergic inhibitor.
71. A method for treating obesity comprising administering a GC--C
receptor agonist and gut hormone fragment peptide YY.sub.3-36,
glp-1 (glucagon-like peptide-1), exendin-4 (an inhibitor of glp-1),
sibutramine, phentermine, phendimetrazine, benzphetamine
hydrochloride (Didrex), orlistat (Xenical), diethylpropion
hydrochloride (Tenuate), fluoxetine (Prozac), bupropion, ephedra,
chromium, garcinia cambogia, benzocaine, bladderwrack (focus
vesiculosus), chitosan, nomame herba, galega (Goat's Rue, French
Lilac), conjugated linoleic acid, L-carnitine, fiber (psyllium,
plantago, guar fiber), caffeine, dehydroepiandrosterone, germander
(teucrium chamaedrys), B-hydroxy-.beta.-methylbutyrate, or
pyruvate.
Description
CLAIM OF PRIORITY
[0001] This application claims priority under 35 USC .sctn. 119(e)
to U.S. Provisional Patent Application Ser. No. 60/443,098, filed
on Jan. 28, 2003; U.S. Provisional Patent Application Ser. No.
60/471,288, filed on May 15, 2003 and U.S. Provisional Patent
Application Ser. No. 60/519,460, filed on Nov. 12, 2003, the entire
contents of which are hereby incorporated by reference.
TECHNICAL FIELD
[0002] This invention relates to methods and compositions for
treating various disorders, including gastrointestinal disorders,
obesity, congestive heart failure and benign prostatic
hyperplasia.
BACKGROUND
[0003] Irritable bowel syndrome (IBS) is a common chronic disorder
of the intestine that affects 20 to 60 million individuals in the
US alone (Lehman Brothers, Global Healthcare-Irritable bowel
syndrome industry update, September 1999). IBS is the most common
disorder diagnosed by gastroenterologists (28% of patients
examined) and accounts for 12% of visits to primary care physicians
(Camilleri 2001, Gastroenterology 120:652-668). In the US, the
economic impact of IBS is estimated at $25 billion annually,
through direct costs of health care use and indirect costs of
absenteeism from work (Talley 1995, Gastroenterology
109:1736-1741). Patients with IBS have three times more absenteeism
from work and report a reduced quality of life. Sufferers may be
unable or unwilling to attend social events, maintain employment,
or travel even short distances (Drossman 1993, Dig Dis Sci
38:1569-1580). There is a tremendous unmet medical need in this
population since few prescription options exist to treat IBS.
[0004] Patients with IBS suffer from abdominal pain and a disturbed
bowel pattern. Three subgroups of IBS patients have been defined
based on the predominant bowel habit: constipation-predominant
(c-IBS), diarrhea-predominant (d-IBS) or alternating between the
two (a-IBS). Estimates of individuals who suffer from c-IBS range
from 20-50% of the IBS patients with 30% frequently cited. In
contrast to the other two subgroups that have a similar gender
ratio, c-IBS is more common in women (ratio of 3:1) (Talley et al.
1995, Am J Epidemiol 142:76-83).
[0005] The definition and diagnostic criteria for IBS have been
formalized in the "Rome Criteria" (Drossman et al. 1999, Gut
45:Suppl II: 1-81), which are well accepted in clinical practice.
However, the complexity of symptoms has not been explained by
anatomical abnormalities or metabolic changes. This has led to the
classification of IBS as a functional GI disorder, which is
diagnosed on the basis of the Rome criteria and limited evaluation
to exclude organic disease.(Ringel et al. 2001, Annu Rev Med 52:
319-338). IBS is considered to be a "biopsychosocial" disorder
resulting from a combination of three interacting mechanisms:
altered bowel motility, an increased sensitivity of the intestine
or colon to pain stimuli (visceral sensitivity) and psychosocial
factors (Camilleri 2001, Gastroenterology 120:652-668). Recently,
there has been increasing evidence for a role of inflammation in
etiology of IBS. Reports indicate that subsets of IBS patients have
small but significant increases in colonic inflammatory and mast
cells, increased inducible nitric oxide (NO) and synthase (iNOS)
and altered expression of inflammatory cytokines (reviewed by
Talley 2000, Medscape Coverage of DDW week).
SUMMARY
[0006] The present invention features compositions and related
methods for treating IBS and other gastrointestinal disorders and
conditions (e.g., gastrointestinal motility disorders, functional
gastrointestinal disorders, gastroesophageal reflux disease (GERD),
Crohn's disease, ulcerative colitis, Inflammatory bowel disease,
functional heartburn, dyspepsia (including functional dyspepsia or
nonulcer dyspepsia), gastroparesis, chronic intestinal
pseudo-obstruction (or colonic pseudo-obstruction), and disorders
and conditions associated with constipation, e.g., constipation
associated with use of opiate pain killers, post-surgical
constipation, and constipation associated with neuropathic
disorders as well as other conditions and disorders. The
compositions feature peptides that activate the guanylate cyclase C
(GC--C) receptor.
[0007] The present invention also features compositions and related
methods for treating obesity, congestive heart failure and benign
prostatic hyperplasia (BPH).
[0008] Without being bound by any particular theory, in the case of
IBS and other gastrointestinal disorders the peptides are useful
because they can increase gastrointestinal motility.
[0009] Without being bound by any particular theory, in the case of
IBS and other gastrointestinal disorders the peptides are useful,
in part, because they can decrease inflammation.
[0010] Without being bound by any particular theory, in the case of
IBS and other gastrointestinal disorders the peptides are also
useful because they can decrease gastrointestinal pain or visceral
pain.
[0011] The invention features pharmaceutical compositions
comprising certain peptides that are capable of activating the
guanylate-cyclase C (GC--C) receptor. Also within the invention are
pharmaceutical compositions comprising a peptide of the invention
as well as combination compositions comprising a peptide of the
invention and a second therapeutic agent, e.g., an agent for
treating constipation (e.g., SPI-0211; Sucampo Pharmaceuticals,
Inc.; Bethesda, Md.) or some other gastrointestinal disorder.
Examples of a second therapeutic agent include: acid reducing
agents such as proton pump inhibitors and H2 receptor blockers,
pro-motility agents such as 5HT receptor agonists (e.g.
Zelnorm.RTM.), anti-inflammatory agents, antispasmodics,
antidepressants, centrally-acting analgesic agents such as opiod
receptor agonists, opiod receptor antagonists, agents for the
treatment of Inflammatory bowel disease, Crohn's disease and
ulcerative colitis (e.g., Traficet-EN.TM. (ChemoCentryx, Inc.; San
Carlos, Calif.) agents that treat gastrointestinal or visceral pain
and cGMP phosphodiesterase inhibitors (motapizone, zaprinast, and
suldinac sulfone). Thus, for example, the pharmaceutical
compositions can include an analgesic agent selected from the group
consisting of: Ca channel blockers (e.g., ziconotide), 5HT receptor
antagonists (for example 5HT3, 5HT4 and 5HT1 receptor antagonists),
opioid receptor agonists (e.g., loperamide, fedotozine, and
fentanyl, naloxone, naltrexone, methyl nalozone, nalmefene,
cypridime, beta funaltrexamine, naloxonazine, naltrindole, and
nor-binaltorphimine, morphine, diphenyloxylate, enkephalin
pentapeptide, and trimebutine), NK1 receptor antagonists (e.g.,
ezlopitant and SR-14033), CCK receptor agonists (e.g.,
loxiglumide), NK1 receptor antagonists, NK3 receptor antagonists
(e.g., talnetant, osanetant (SR-142801)), norepinephrine-serotonin
reuptake inhibitors (NSRI; e.g., milnacipran), vanilloid and
cannabanoid receptor agonists (e.g., arvanil), sialorphin,
sialorphin-related peptides comprising the amino acid sequence
QHNPR (SEQ ID NO:111) for example, VQHNPR (SEQ ID NO:112); VRQHNPR
(SEQ ID NO:113); VRGQHNPR (SEQ ID NO:114); VRGPQHNPR (SEQ ID
NO:115); VRGPRQHNPR (SEQ ID NO:116); VRGPRRQHNPR (SEQ ID NO:117);
and RQHNPR (SEQ ID NO:118), compounds or peptides that are
inhibitors of neprilysin, frakefamide
(H-Tyr-D-Ala-Phe(F)-Phe-NH.sub.2; WO 01/019849 A1), loperamide,
Tyr-Arg (kyotorphin), CCK receptor agonists (caerulein), conotoxin
peptides, peptide analogs of thymulin, loxiglumide, dexloxiglumide
(the R-isomer of loxiglumide) (WO 88/05774) and other analgesic
peptides or compounds can be used with or linked to the peptides of
the invention.
[0012] The invention includes methods for treating various
gastrointestinal disorders by administering a peptide that acts as
a partial or complete agonist of the GC--C receptor. The peptide
includes at least six cysteines that form three disulfide bonds. In
certain embodiments the disulfide bonds are replaced by other
covalent cross-links and in some cases the cysteines are
substituted by other residues to provide for alternative covalent
cross-links. The peptides may also include at least one trypsin or
chymotrypsin cleavage site and/or a carboxy-terminal analgesic
peptide or small molecule, e.g., AspPhe or some other analgesic
peptide. When present within the peptide, the analgesic peptide or
small molecule may be preceded by a chymotrypsin or trypsin
cleavage site that allows release of the analgesic peptide or small
molecule. The peptides and methods of the invention are also useful
for treating pain and inflammation associated with various
disorders, including gastrointestinal disorders. Certain peptides
include a functional chymotrypsin or trypsin cleavage site located
so as to allow inactivation of the peptide upon cleavage. Certain
peptides having a functional cleavage site undergo cleavage and
gradual inactivation in the digestive tract, and this is desirable
in some circumstances. In certain peptides, a functional
chymotrypsin site is altered, increasing the stability of the
peptide in vivo.
[0013] The invention includes methods for treating other disorders
such as congestive heart failure and benign prostatic hyperplasia
by administering a peptide or small molecule (parenterally or
orally) that acts as an agonist of the GC--C receptor. Such agents
can be used in combination with natriuretic peptides (e.g., atrial
natriuretic peptide, brain natriuretic peptide or C-type
natriuretic peptide), a diuretic, or an inhibitor of angiotensin
converting enzyme.
[0014] The invention features methods and compositions for
increasing intestinal motility. Intestinal motility involves
spontaneous coordinated dissentions and contractions of the
stomach, intestines, colon and rectum to move food through the
gastrointestinal tract during the digestive process.
[0015] In certain embodiments the peptides include either one or
two or more contiguous negatively charged amino acids (e.g., Asp or
Glu) or one or two or more contiguous positively charged residues
(e.g., Lys or Arg) or one or two or more contiguous positively or
negatively charged amino acids at the carboxy terminus. In these
embodiments all of the flanking amino acids at the carboxy terminus
are either positively or negatively charged. In other embodiments
the carboxy terminal charged amino acids are preceded by a Leu. For
example, the following amino acid sequences can be added to the
carboxy terminus of the peptide: Asp; Asp Lys; Lys Lys Lys Lys Lys
Lys (SEQ ID NO:123); Asp Lys Lys Lys Lys Lys Lys (SEQ ID NO:124);
Leu Lys Lys; and Leu Asp. It is also possible to simply add Leu at
the carboxy terminus.
[0016] In a first aspect, the invention features a peptide
comprising, consisting of, or consisting essentially of the amino
acid sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4
Xaa.sub.5 Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10
Cys.sub.11 Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16
Xaa.sub.17 Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID
NO:119) wherein: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa4 Xaa.sub.5 is
Asn Ser Ser Asn Tyr (SEQ ID NO:121) or is missing or Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 is missing. In certain embodiments
Xaa.sub.8, Xaa.sub.9, Xaa.sub.12, Xaa.sub.13, Xaa.sub.14,
Xaa.sub.17, and Xaa.sub.19 can be any amino acid. In certain
embodiments Xaa.sub.5 is Asn, Trp, Tyr, Asp, or Phe. In other
embodiments, Xaa.sub.5 can also be Thr or Ile. In other embodiments
Xaa.sub.5 is Tyr, Asp or Trp. In some embodiments Xaa.sub.8 is Glu,
Asp, Gln, Gly or Pro. In other embodiments Xaa.sub.8 is Glu; in
some embodiments Xaa.sub.9 is Leu, Ile, Val, Ala, Lys, Arg, Trp,
Tyr or Phe in some embodiments Xaa.sub.9 is Leu, Ile, Val, Lys,
Arg, Trp, Tyr or Phe.
[0017] In certain embodiments, an amino acid can be replace by a
non-naturally occurring amino acid or a naturally or non-naturally
occurring amino acid analog. For example, an aromatic amino acid
can be replaced by 3,4-dihydroxy-L-phenylalanine,
3-iodo-L-tyrosine, triiodothyronine, L-thyroxine, phenylglycine
(Phg) or nor-tyrosine (norTyr). Phg and norTyr and other amino
acids including Phe and Tyr can be substituted by, e.g., a halogen,
--CH3, --OH, --CH.sub.2NH.sub.3, --C(O)H, --CH.sub.2CH.sub.3, --CN,
--CH.sub.2CH.sub.2CH.sub.3, --SH, or another group.
[0018] In some embodiments Xaa.sub.12 is Asn, Tyr, Asp or Ala. In
other embodiments Xaa.sub.12 is Asn. In some embodiments Xaa.sub.13
is Ala, Pro or Gly, and in other embodiments it is Pro. In some
embodiments Xaa.sub.14 is Ala, Leu, Ser, Gly, Val, Glu, Gln, Ile,
Leu, Lys, Arg, or Asp, and in other embodiments it is Ala or Gly,
and in still other embodiments it is Ala. In some embodiments
Xaa.sub.16 is Thr, Ala, Asn, Lys, Arg, Trp; Xaa.sub.17 is Gly, Pro
or Ala; Xaa.sub.19 is selected from Trp, Tyr, Phe, Asn and Leu or
Xaa.sub.19 is selected from Tip, Tyr, and Phe or Xaa.sub.19 is
selected from Leu, Ile and Val; or Xaa.sub.19 is His or Xaa.sub.19
is selected from Trp, Tyr, Phe, Asn, Ile, Val, His and Leu; and
Xaa.sub.20 Xaa.sub.21 is AspPhe or is missing or Xaa.sub.20 is Asn
or Glu and Xaa.sub.21 is missing or Xaa.sub.19 Xaa.sub.20
Xaa.sub.21 is missing. The invention also features methods for
treating a gastrointestinal disorder (e.g., a gastrointestinal
motility disorder, a functional gastrointestinal disorder,
gastroesophageal reflux disease, functional heartburn, dyspepsia,
functional dyspepsia, nonulcer dyspepsia, gastroparesis, chronic
intestinal pseudo-obstruction, colonic pseudo-obstruction),
obesity, congestive heart failure or benign prostatic hyperplasia
by administering a composition comprising an aforementioned
peptide
[0019] When Xaa.sub.9 is Trp, Tyr or Phe or when Xaa.sub.16 is Trp
the peptide has a potentially functional chymotrypsin cleavage site
that is located at a position where cleavage will inactivate GC--C
receptor binding by the peptide. When Xaa.sub.9 is Lys or Arg or
when Xaa.sub.16 is Lys or Arg, the peptide has a potentially
functional trypsin cleavage site that is located at a position
where cleavage will inactivate GC--C receptor binding by the
peptide.
[0020] When Xaa.sub.19 is Trp, Tyr or Phe, the peptide has a
chymotrypsin cleavage site that is located at a position where
cleavage will liberate the portion of the peptide carboxy-terminal
to Xaa.sub.19. When Xaa.sub.19 is Leu, Ile or Val, the peptide can
have a chymotrypsin cleavage site that is located at a position
where cleavage will liberate the portion of the peptide
amino-terminal to Xaa.sub.19. At relatively high pH the same effect
is seen when Xaa.sub.19 is His. When Xaa.sub.19 is Lys or Arg, the
peptide has a trypsin cleavage site that is located at a position
where cleavage will liberate portion of the peptide
carboxy-terminal to Xaa.sub.19. Thus, if the peptide includes an
analgesic peptide carboxy-terminal to Xaa.sub.19, the peptide will
be liberated in the digestive tract upon exposure to the
appropriate protease. Among the analgesic peptides which can be
included in the peptide are: AspPhe (as Xaa.sub.20Xaa.sub.21),
endomorphin-1, endomorphin-2, nocistatin, dalargin, lupron, and
substance P and other analgesic peptides described herein. These
peptides can, for example, be used to replace
Xaa.sub.20Xaa.sub.21.
[0021] When Xaa.sub.1 or the amino-terminal amino acid of the
peptide of the invention (e.g., Xaa.sub.2 or Xaa.sub.3) is Trp, Tyr
or Phe, the peptide has a chymotrypsin cleavage site that is
located at a position where cleavage will liberate the portion of
the peptide amino-terminal to Xaa.sub.1 (or Xaa.sub.2 or Xaa.sub.3)
along with Xaa.sub.1, Xaa.sub.2 or Xaa.sub.3. When Xaa.sub.1 or the
amino-terminal amino acid of the peptide of the invention (e.g.,
Xaa.sub.2 or Xaa.sub.3) is Lys or Arg, the peptide has a trypsin
cleavage site that is located at a position where cleavage will
liberate portion of the peptide amino-terminal to Xaa.sub.1 along
with Xaa.sub.1, Xaa.sub.2 or Xaa.sub.3). When Xaa.sub.1 or the
amino-terminal amino acid of the peptide of the invention is Leu,
Ile or Val, the peptide can have a chymotrypsin cleavage site that
is located at a position where cleavage will liberate the portion
of the peptide amino-terminal to Xaa.sub.1. At relatively high pH
the same effect is seen when Xaa.sub.1 is His. Thus, for example,
if the peptide includes an analgesic peptide amino-terminal to
Xaa.sub.1, the peptide will be liberated in the digestive tract
upon exposure to the, appropriate protease. Among the analgesic
peptides which can be included in the peptide are: AspPhe,
endomorphin-1, endomorphin-2, nocistatin, dalargin, lupron, and
substance p and other analgesic peptides described herein.
[0022] When fully folded, disulfide bonds are present between:
Cys.sub.6 and Cys.sub.11; Cys.sub.7 and Cys.sub.15; and Cys.sub.10
and Cys.sub.18. The peptides of the invention bear some sequence
similarity to ST peptides. However, they include amino acid changes
and/or additions that improve functionality. These changes can, for
example, increase or decrease activity (e.g., increase or decrease
the ability of the peptide to stimulate intestinal motility), alter
the ability of the peptide to fold correctly, the stability of the
peptide, the ability of the peptide to bind the GC--C receptor
and/or decrease toxicity. In some cases the peptides may function
more desirably than wild-type ST peptide. For example, they may
limit undesirable side effects such as diarrhea and
dehydration.
[0023] In some embodiments one or both members of one or more pairs
of Cys residues which normally form a disulfide bond can be
replaced by homocysteine, 3-mercaptoproline (Kolodziej et al. 1996
Int J Pept Protein Res 48:274); .beta., .beta. dimethylcysteine
(Hunt et al. 1993 Int J Pept Protein Res 42:249) or
diaminopropionic acid (Smith et al. 1978 J Med Chem 21:117) to form
alternative internal cross-links at the positions of the normal
disulfide bonds.
[0024] In addition, one or more disulfide bonds can be replaced by
alternative covalent cross-links, e.g., an amide bond, an ester
linkage, an alkyl linkage, a thio ester linkage, a lactam bridge, a
carbamoyl linkage, a urea linkage, a thiourea linkage, a
phosphonate ester linkage, an alkyl linkage, and alkenyl linkage,
an ether, a thioether linkage, or an amino linkage. For example,
Ledu et al. (Proceedings Nat'l Acad. Sci. 100:11263-78, 2003)
described methods for preparing lactam and amide cross-links.
Schafmneister et al. (J. Am. Chem. Soc. 122:5891, 2000) describes
stable, all carbon cross-links. In some cases, the generation of
such alternative cross-links requires replacing the Cys residues
with other residues such as Lys or Glu or non-naturally occurring
amino acids.
[0025] In the case of a peptide comprising the sequence (I):
Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys.sub.6
Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11 Xaa.sub.12
Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17 Cys.sub.18
Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID NO:119)wherein: Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is missing and/or the
sequence Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 is missing, the peptide
can still contain additional carboxyterminal or amino terminal
amino acids or both. For example, the peptide can include an amino
terminal sequence that facilitates recombinant production of the
peptide and is cleaved prior to administration of the peptide to a
patient. The peptide can also include other amino terminal or
carboxyterminal amino acids. In some cases the additional amino
acids protect the peptide, stabilize the peptide or alter the
activity of the peptide. In some cases some or all of these
additional amino acids are removed prior to administration of the
peptide to a patient. The peptide can include 1, 2, 3, 4, 5, 10,
15, 20, 25, 30, 40, 50, 60, 70 80, 90, 100 or more amino acids at
its amino terminus or carboxy terminus or both. The number of
flanking amino acids need not be the same. For example, there can
be 10 additional amino acids at the amino terminus of the peptide
and none at the carboxy terminus.
[0026] In one embodiment the peptide comprises the amino acid
sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11
Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17
Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID NO:119)
wherein: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is
missing; Xaa.sub.8 is Glu; Xaa.sub.9 is Leu, Ile, Lys, Arg, Trp,
Tyr or Phe; Xaa.sub.12 is Asn; Xaa.sub.13 is Pro; Xaa.sub.14 is
Ala; Xaa.sub.16 is Thr, Ala, Lys, Arg, Trp; Xaa.sub.17 is Gly;
Xaa.sub.19 is Tyr or Leu; and Xaa.sub.20 Xaa.sub.21 is AspPhe or is
missing. Where Xaa.sub.20 Xaa.sub.21 and/or Xaa.sub.1 Xaa.sub.2
Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 are missing, there may be additional
flanking amino acids in some embodiments.
[0027] In a second aspect, the invention also features a
therapeutic or prophylactic method comprising administering a
peptide comprising the amino acid sequence (I): Xaa.sub.1 Xaa.sub.2
Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys.sub.6 Cys.sub.7 Xaa.sub.8
Xaa.sub.9 Cys.sub.10 Cys.sub.11 Xaa.sub.12 Xaa.sub.13 Xaa.sub.14
Cys.sub.15 Xaa.sub.17 Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21
(SEQ ID NO:119) wherein: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4
Xaa.sub.5 is Asn Ser Ser Asn Tyr (SEQ ID NO:121) or is missing or
Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 is missing and Xaa.sub.5 is
Asn, Trp, Tyr, Asp, Ile, Thr, or Phe; Xaa.sub.8 is Glu, Asp, Gln,
Gly or Pro; Xaa.sub.9 is Leu, Ile, Val, Ala, Lys, Arg, Trp, Tyr or
Phe; Xaa.sub.12 is Asn, Tyr, Asp or Ala; Xaa.sub.13 is Pro or Gly;
Xaa.sub.14 is Ala, Leu, Ser, Gly, Val, Glu, Gln, Ile, Leu, Lys,
Arg, and Asp; Xaa.sub.16 is Thr, Ala, Asn, Lys, Arg, Trp;
Xaa.sub.17 is Gly, Pro or Ala; Xaa.sub.19 is Trp, Tyr, Phe or Leu;
and Xaa.sub.20 Xaa.sub.21 is AspPhe or is missing or Xaa.sub.20 is
Asn or Glu and Xaa.sub.21 is missing or Xaa.sub.19 Xaa.sub.20
Xaa.sub.21 is missing.
[0028] In certain embodiments of the therapeutic or prophylactic
methods: the peptide comprises the amino acid sequence (I):
Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys.sub.6
Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11 Xaa.sub.12
Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17 Cys.sub.18
Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID NO:119) wherein: Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is missing; Xaa.sub.8 is
Glu; Xaa.sub.9 is Leu, Ile, Lys, Arg, Trp, Tyr, or Phe; Xaa.sub.12
is Asn; Xaa.sub.13 is Pro; Xaa.sub.14 is Ala; Xaa.sub.16 is Thr,
Ala, Lys, Arg, Trp or Xaa.sub.16 is any amino acid or Xaa.sub.16 is
Thr, Ala, Lys, Arg, Trp or Xaa.sub.16 is any non-aromatic amino
acid; Xaa.sub.17 is Gly; Xaa.sub.19 is Tyr or Leu; and Xaa.sub.20
Xaa.sub.21 is AspPhe or is missing.
[0029] In certain embodiments, the invention features, a purified
polypeptide comprising the amino acid sequence (II):
[0030] Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys.sub.6
Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11 Asn.sub.12
Pro.sub.13 Ala.sub.14 Cys.sub.15 Xaa.sub.16 Gly.sub.17 Cys.sub.18
Xaa.sub.19 Xaa.sub.20Xaa.sub.21 (SEQ ID NO:120) wherein
[0031] Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is Asn Ser
Ser Asn Tyr (SEQ ID NO:121) or is missing or Xaa.sub.1 Xaa.sub.2
Xaa.sub.3 Xaa.sub.4 is missing and Xaa.sub.5 is Asn;
[0032] Xaa.sub.8 is Glu or Asp;
[0033] Xaa.sub.9 is Leu, Ile, Val, Trp, Tyr or Phe;
[0034] Xaa.sub.16 is Thr, Ala, Trp;
[0035] Xaa.sub.19 is Trp, Tyr, Phe or Leu or is missing; and
Xaa.sub.20 Xaa.sub.21 is AspPhe.
[0036] In various preferred embodiments the invention features a
purified polypeptide comprising the amino acid sequence (II):
Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys.sub.6
Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11 Asn.sub.12
Pro.sub.13 Ala.sub.14 Cys.sub.15 Xaa.sub.16 Gly.sub.17 Cys.sub.18
Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID NO:120) wherein, Xaa.sub.9
is Leu, Ile or Val and Xaa.sub.16 is Trp, Tyr or Phe; Xaa.sub.9 is
Trp, Tyr or Phe, and Xaa.sub.16 is Thr or Ala; Xaa.sub.19 is Trp,
Tyr, Phe and Xaa.sub.20 Xaa.sub.21 is AspPhe; and Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 is missing and Xaa.sub.5 is Asn; the
peptide comprises fewer than 50, 40, 30 or 25 amino acids; fewer
than five amino acid precede Cys.sub.6.
[0037] The peptides can be co-administered with or linked, e.g.,
covalently linked to any of a variety of other peptides including
analgesic peptides or analgesic compounds. For example, a
therapeutic peptide of the invention can be linked to an analgesic
agent selected from the group consisting of: Ca channel blockers
(e.g., ziconotide), complete or partial 5HT receptor antagonists
(for example 5HT3, 5HT4 and 5HT1 receptor antagonists), complete or
partial 5HT receptor agonists including 5HT3, 5HT4 (for example
tegaserod, mosapride and renzapride) and 5HT1 receptor agonists,
CRF receptor agonists (NBI-34041), .beta.-3 adrenoreceptor
agonists, opioid receptor agonists (e.g., loperamide, fedotozine,
and fentanyl, naloxone, naltrexone, methyl nalozone, nalmefene,
cypridime, beta funaltrexamine, naloxonazine, naltrindole, and
nor-binaltorphimine, morphine, diphenyloxylate, enkephalin
pentapeptide, asimadoline, and trimebutine), NK1 receptor
antagonists (e.g., ezlopitant and SR-14033), CCK receptor agonists
(e.g., loxiglumide), NK1 receptor antagonists, NK3 receptor
antagonists (e.g., talnetant, osanetant (SR-142801)),
norepinephrine-serotonin reuptake inhibitors (NSRI; e.g.,
milnacipran), vanilloid and cannabanoid receptor agonists (e.g.,
arvanil), sialorphin, sialorphin-related peptides comprising the
amino acid sequence QHNPR (SEQ ID NO:111) for example, VQHNPR (SEQ
ID NO:112); VRQHNPR (SEQ ID NO:113); VRGQHNPR (SEQ ID NO:114);
VRGPQHNPR (SEQ ID NO:115); VRGPRQHNPR (SEQ ID NO:116); VRGPRRQHNPR
(SEQ ID NO:117); and RQHNPR (SEQ ID NO:118), compounds or peptides
that are inhibitors of neprilysin, frakefamide
(H-Tyr-D-Ala-Phe(F)-Phe-NH.sub.2; WO 01/019849 A1), loperamide,
Tyr-Arg (kyotorphin), CCK receptor agonists (caerulein), conotoxin
peptides, pepetide analogs of thymulin, loxiglumide, dexloxiglumide
(the R-isomer of loxiglumide) (WO 88/05774) and other analgesic
peptides or compounds can be used with or linked to the peptides of
the invention.
[0038] Amino acid, non-amino acid, peptide and non-peptide spacers
can be interposed between a peptide that is a GC--C receptor
agonsit and a peptide that has some other biological function,
e.g., an analgesic peptide or a peptide used to treat obesity. The
linker can be one that is cleaved from the flanking peptides in
vivo or one that remains linked to the flanking peptides in vivo.
For example, glycine, beta-alanine, glycyl-glycine,
glycyl-beta-alanine, gamma-aminobutyric acid, 6-aminocaproic acid,
L-phenylalanine, L-tryptophan and glycil-L-valil-L-phenylalanine
can be used as a spacer (Chaltin et al. 2003 Helvetica Chimica Acta
86:533-547; Caliceti et al. 1993 FARMCO 48:919-32) as can
polyethylene glycols (Butterworth et al. 1987 J. Med. Chem
30:1295-302) and maleimide derivatives (King et al. 2002
Tetrahedron Lett. 43:1987-1990). Various other linkers are
described in the literature (Nestler 1996 Molecular Diversity
2:35-42; Finn et al. 1984 Biochemistry 23:2554-8; Cook et al. 1994
Tetrahedron Lett. 35:6777-80; Brokx et al. 2002 Journal of
Controlled Release 78:115-123; Griffin et al. 2003 J. Am. Chem.
Soc. 125:6517-6531; Robinson et al. 1998 Proc. Natl. Acad. Sci. USA
95:5929-5934.
[0039] The peptides can include the amino acid sequence of a
peptide that occurs naturally in a vertebrate (e.g., mammalian)
species or in a bacterial species. In addition, the peptides can be
partially or completely non-naturally occurring peptides. Also
within the invention are peptidomimetics corresponding to the
peptides of the invention. In various embodiments, the patient is
suffering from a gastrointestinal disorder; the patient is
suffering from a disorder selected from the group consisting of: a
gastrointestinal motility disorder, irritable bowel syndrome,
chronic constipation, a functional gastrointestinal disorder,
gastroesophageal reflux disease, functional heartburn, dyspepsia,
functional dyspepsia, nonulcer dyspepsia, gastroparesis, chronic
intestinal pseudo-obstruction, Crohn's disease, ulcerative colitis,
Irritable bowel syndrome, colonic pseudo-obstruction, obesity,
congestive heart failure, or benign prostatic hyperplasia; the
composition is administered orally; the peptide comprises 30 or
fewer amino acids, the peptide comprises 20 or fewer amino acids,
and the peptide comprises no more than 5 amino acids prior to
Cys.sub.6; the peptide comprises 150, 140, 130, 120, 110, 100, 90,
80, 70, 60, 50, 40, or 30 or fewer amino acids. In other
embodiments, the peptide comprises 20 or fewer amino acids. In
other embodiments the peptide comprises no more than 20, 15, 10, or
5 peptides subsequent to Cys.sub.18. In certain embodiments
Xaa.sub.19 is a chymotrypsin or trypsin cleavage site and an
analgesic peptide is present immediately following Xaa.sub.19.
[0040] In a third aspect, the invention features a method for
treating a patient suffering from constipation. Clinically accepted
criteria that define constipation range from the frequency of bowel
movements, the consistency of feces and the ease of bowel movement.
One common definition of constipation is less than three bowel
movements per week. Other definitions include abnormally hard
stools or defecation that requires excessive straining (Schiller
2001, Aliment Pharmacol Ther 15:749-763). Constipation may be
idiopathic (functional constipation or slow transit constipation)
or secondary to other causes including neurologic, metabolic or
endocrine disorders. These disorders include diabetes mellitus,
hypothyroidism, hyperthyroidism, hypocalcaemia, Multiple Sclerosis,
Parkinson's disease, spinal cord lesions, Neurofibromatosis,
autonomic neuropathy, Chagas disease, Hirschsprung's disease and
Cystic fibrosis. Constipation may also be the result of surgery
(postoperative ileus) or due to the use of drugs such as analgesics
(like opiods), antihypertensives, anticonvulsants, antidepressants,
antispasmodics and antipsychotics.
[0041] The method comprising administering a composition comprising
a purified polypeptide comprising the amino acid sequence (I):
Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys.sub.6
Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11 Xaa.sub.12
Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17 Cys.sub.18
Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID NO:119) wherein: Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is Asn Ser Ser Asn Tyr (SEQ
ID NO:121) or is missing or Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4
is missing and Xaa.sub.5 is Asn, Trp, Tyr, Asp, Ile, Thr, or Phe;
Xaa.sub.8 is Glu, Asp, Gln, Gly or Pro; Xaa.sub.9 is Leu, Ile, Val,
Ala, Lys, Arg, Trp, Tyr or Phe; Xaa.sub.12 is Asn, Tyr, Asp or Ala;
Xaa.sub.13 is Pro or Gly; Xaa.sub.14 is Ala, Leu, Ser, Gly, Val,
Glu, Gln, Ile, Leu, Lys, Arg, and Asp; Xaa.sub.16 is Thr, Ala, Asn,
Lys, Arg, Trp; Xaa.sub.17 is Gly, Pro or Ala; Xaa.sub.19 is Trp,
Tyr, Phe or Leu; Xaa.sub.19 is Lys or Arg; Xaa.sub.20 Xaa.sub.21 is
AspPhe or is missing or Xaa.sub.20 is Asn or Glu and Xaa.sub.21 is
missing or Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 is missing.
[0042] In one embodiment of the method, the peptide comprises the
amino acid sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4
Xaa.sub.5 Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10
Cys.sub.11 Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16
Xaa.sub.17 Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID
NO:119) wherein: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
is missing; Xaa.sub.8 is Glu; Xaa.sub.9 is Leu, Ile, Lys, Arg, Trp,
Tyr or Phe; Xaa.sub.12 is Asn; Xaa.sub.13 is Pro; Xaa.sub.14 is
Ala; Xaa.sub.16 is Thr, Ala, Lys, Arg, Trp; Xaa.sub.17 is Gly;
Xaa.sub.19 is Tyr or Leu; Xaa.sub.19 is Lys or Arg; Xaa.sub.20
Xaa.sub.21 is AspPhe or is missing.
[0043] In various preferred embodiments, the constipation is
associated with use of a therapeutic agent; the constipation is
associated with a neuropathic disorder; the constipation is
post-surgical constipation (postoperative ileus); and the
constipation associated with a gastrointestinal disorder; the
constipation is idiopathic (functional constipation or slow transit
constipation); the constipation is associated with neuropathic,
metabolic or endocrine disorder (e.g., diabetes mellitus,
hypothyroidism, hyperthyroidism, hypocalcaemia, Multiple Sclerosis,
Parkinson's disease, spinal cord lesions, neurofibromatosis,
autonomic neuropathy, Chagas disease, Hirschsprung's disease or
cystic fibrosis). Constipation may also be the result of surgery
(postoperative ileus) or due the use of drugs such as analgesics
(e.g., opiods), antihypertensives, anticonvulsants,
antidepressants, antispasmodics and antipsychotics.
[0044] In a fourth aspect, the invention features a method for
treating a patient suffering a gastrointestinal disorder, the
method comprising administering to the patient a composition
comprising a purified polypeptide comprising the amino acid
sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11
Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17
Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID NO:119)
wherein: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is Asn
Ser Ser Asn Tyr (SEQ ID NO:121) or is missing or Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 is missing and Xaa.sub.5 is Asn, Trp,
Tyr, Asp, Ile, Thr, or Phe; Xaa.sub.8 is Glu, Asp, Gln, Gly or Pro;
Xaa.sub.9 is Leu, Ile, Val, Ala, Lys, Arg, Trp, Tyr or Phe;
Xaa.sub.12 is Asn, Tyr, Asp or Ala; Xaa.sub.13 is Pro or Gly;
Xaa.sub.14 is Ala, Leu, Ser, Gly, Val, Glu, Gln, Ile, Leu, Lys,
Arg, and Asp; Xaa.sub.16 is Thr, Ala, Asn, Lys, Arg, Trp;
Xaa.sub.17 is Gly, Pro or Ala; Xaa.sub.19 is Trp, Tyr, Phe or Leu;
Xaa.sub.19 is Lys or Arg;Xaa.sub.20 Xaa.sub.21 is AspPhe or is
missing or Xaa.sub.20 is Asn or Glu and Xaa.sub.21 is missing or
Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 is missing.
[0045] In one embodiment of the method, the peptide comprises the
amino acid sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4
Xaa.sub.5 Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10
Cys.sub.11 Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16
Xaa.sub.17 Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID
NO:119) wherein: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
is missing; Xaa.sub.8 is Glu; Xaa.sub.9 is Leu, Ile, Lys, Arg, Trp,
Tyr or Phe; Xaa.sub.12 is Asn; Xaa.sub.13 is Pro; Xaa.sub.14 is
Ala; Xaa.sub.16 is Thr, Ala, Lys, Arg, Trp; Xaa.sub.17 is Gly;
Xaa.sub.19 is Tyr or Leu; Xaa.sub.19 is Lys or Arg; Xaa.sub.20
Xaa.sub.21 is AspPhe or is missing.
[0046] In various embodiments, the patient is suffering from a
gastrointestinal disorder; the patient is suffering from a disorder
selected from the group consisting of: a gastrointestinal motility
disorder, irritable bowel syndrome, chronic constipation, a
functional gastrointestinal disorder, gastroesophageal reflux
disease, functional heartburn, dyspepsia, functional dyspepsia,
nonulcer dyspepsia, gastroparesis, chronic intestinal
pseudo-obstruction, Crohn's disease, ulcerative colitis,
Inflammatory bowel disease, colonic pseudo-obstruction, obesity,
congestive heart failure, or benign prostatic hyperplasia.
[0047] In various preferred embodiments, Xaa.sub.9 is Leu, Ile or
Val and Xaa.sub.16 is Trp, Tyr or Phe; Xaa.sub.9 is Trp, Tyr or Phe
and Xaa.sub.16 is Thr or Ala; Xaa.sub.19 is Trp, Tyr, Phe;
Xaa.sub.19 is Lys or Arg;Xaa.sub.20 Xaa.sub.21 is AspPhe; Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 is missing and Xaa.sub.5 is Asn.
[0048] In a fifth aspect, the invention features a method for
increasing gastrointestinal motility in a patient, the method
comprising: administering to the patient a composition comprising a
purified polypeptide comprising the amino acid sequence (I):
Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys.sub.6
Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11 Xaa.sub.12
Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17 Cys.sub.18
Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID NO:119) wherein: Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is Asn Ser Ser Asn Tyr (SEQ
ID NO:121) or is missing or Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4
is missing and Xaa.sub.5 is Asn, Trp, Tyr, Asp, Ile, Thr, or Phe;
Xaa.sub.8 is Glu, Asp, Gln, Gly or Pro; Xaa.sub.9 is Leu, Ile, Val,
Ala, Lys, Arg, Trp, Tyr or Phe; Xaa.sub.12 is Asn, Tyr, Asp or Ala;
Xaa.sub.13 is Pro or Gly; Xaa.sub.14 is Ala, Leu, Ser, Gly, Val,
Glu, Gln, Ile, Leu, Lys, Arg, and Asp; Xaa.sub.16 is Thr, Ala, Asn,
Lys, Arg, Trp; Xaa.sub.17 is Gly, Pro or Ala; Xaa.sub.19 is Trp,
Tyr, Phe or Leu; Xaa.sub.19 is Lys or Arg; Xaa.sub.20 Xaa.sub.21 is
AspPhe or is missing or Xaa.sub.20 is Asn or Glu and Xaa.sub.21 is
missing or Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 is missing.
[0049] In one embodiment the peptide comprises the amino acid
sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11
Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17
Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID NO:119)
wherein: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is
missing; Xaa.sub.8 is Glu; Xaa.sub.9 is Leu, Ile, Lys, Arg, Trp,
Tyr or Phe; Xaa.sub.12 is Asn; Xaa.sub.13 is Pro; Xaa.sub.14 is
Ala; Xaa.sub.16 is Thr, Ala, Lys, Arg, Trp; Xaa.sub.17 is Gly;
Xaa.sub.19 is Tyr or Leu; Xaa.sub.19 is Lys or Arg; Xaa.sub.20
Xaa.sub.21 is AspPhe or is missing.
[0050] In a sixth aspect, the invention features a method for
increasing the activity of an intestinal guanylate cyclase (GC--C)
receptor in a patient, the method comprising: administering to the
patient a composition comprising a purified polypeptide comprising
the amino acid sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3
Xaa.sub.4 Xaa.sub.5 Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9
Cys.sub.10 Cys.sub.11 Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15
Xaa.sub.16 Xaa.sub.17 Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21
(SEQ ID NO:119) wherein: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4
Xaa.sub.5 is Asn Ser Ser Asn Tyr (SEQ ID NO:121) or is missing or
Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 is missing and Xaa.sub.5 is
Asn, Trp, Tyr, Asp, Ile, Thr, or Phe; Xaa.sub.8 is Glu, Asp, Gln,
Gly or Pro; Xaa.sub.9 is Leu, Ile, Val, Ala, Lys, Arg, Trp, Tyr or
Phe; Xaa.sub.12 is Asn, Tyr, Asp or Ala; Xaa.sub.13 is Pro or Gly;
Xaa.sub.14 is Ala, Leu, Ser, Gly, Val, Glu, Gln, Ile, Leu, Lys,
Arg, and Asp; Xaa.sub.16 is Thr, Ala, Asn, Lys, Arg, Trp;
Xaa.sub.17 is Gly, Pro or Ala; Xaa.sub.19 is Trp, Tyr, Phe or Leu;
Xaa.sub.19 is Lys or Arg; Xaa.sub.20 Xaa.sub.21 is AspPhe or is
missing or Xaa.sub.20 is Asn or Glu and Xaa.sub.21 is missing or
Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 is missing.
[0051] In one embodiment the peptide comprises the amino acid
sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11
Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17
Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID NO:119)
wherein: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is
missing; Xaa.sub.8 is Glu; Xaa.sub.9 is Leu, Ile, Lys, Arg, Trp,
Tyr or Phe; Xaa.sub.12 is Asn; Xaa.sub.13 is Pro; Xaa.sub.14 is
Ala; Xaa.sub.16 is Thr, Ala, Lys, Arg, Trp; Xaa.sub.17 is Gly;
Xaa.sub.19 is Tyr or Leu; Xaa.sub.19 is Lys or Arg; Xaa.sub.20
Xaa.sub.21 is AspPhe or is missing.
[0052] In a seventh aspect, the invention features an isolated
nucleic acid molecule comprising a nucleotide sequence encoding a
polypeptide comprising the amino acid sequence: (I): Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys.sub.6 Cys.sub.7
Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11 Xaa.sub.12 Xaa.sub.13
Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17 Cys.sub.18 Xaa.sub.19
Xaa.sub.20Xaa.sub.21 (SEQ ID NO:119) wherein: Xaa.sub.1 Xaa.sub.2
Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is Asn Ser Ser Asn Tyr or is missing
or Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 is missing and Xaa.sub.5
is Asn, Trp, Tyr, Asp, Ile, Thr, or Phe; Xaa.sub.8 is Glu, Asp,
Gln, Gly or Pro; Xaa.sub.9 is Leu, Ile, Val, Ala, Lys, Arg, Trp,
Tyr or Phe; Xaa.sub.12 is Asn, Tyr, Asp or Ala; Xaa.sub.13 is Pro
or Gly; Xaa.sub.14 is Ala, Leu, Ser, Gly, Val, Glu, Gln, Ile, Leu,
Lys, Arg, and Asp; Xaa.sub.16 is Thr, Ala, Asn, Lys, Arg, Trp;
Xaa.sub.17 is Gly, Pro or Ala; Xaa.sub.19 is Trp, Tyr, Phe or Leu;
Xaa.sub.19 is Lys or Arg; Xaa.sub.20 Xaa.sub.21 is AspPhe or is
missing or Xaa.sub.20 is Asn or Glu and Xaa.sub.21 is missing or
Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 is missing.
[0053] In one embodiment the peptide comprises the amino acid
sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11
Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17
Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID NO:119)
wherein: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is
missing; Xaa.sub.8 is Glu; Xaa.sub.9 is Leu, Ile, Lys, Arg, Trp,
Tyr or Phe; Xaa.sub.12 is Asn; Xaa.sub.13 is Pro; Xaa.sub.14 is
Ala; Xaa.sub.16 is Thr, Ala, Lys, Arg, Trp; Xaa.sub.17 is Gly;
Xaa.sub.19 is Tyr or Leu; Xaa.sub.19 is Lys or Arg; Xaa.sub.20
Xaa.sub.21 is AspPhe or is missing.
[0054] In an eighth aspect the invention features a method for
treating constipation, the method comprising administering an
agonist of the intestinal guanylate cyclase (GC--C) receptor. In
various embodiments: the agonist is a peptide, the peptide includes
four Cys that form two disulfide bonds, and the peptide includes
six Cys that form three disulfide bonds.
[0055] In a ninth aspect, the invention features a method for
treating a gastrointestinal disorder, a gastrointestinal motility
disorder, irritable bowel syndrome, chronic constipation, a
functional gastrointestinal disorder, gastroesophageal reflux
disease, functional heartburn, dyspepsia, functional dyspepsia,
nonulcer dyspepsia, gastroparesis, chronic intestinal
pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease,
ulcerative colitis, Inflammatory bowel disease, obesity, congestive
heart failure, or benign prostatic hyperplasia, the method
comprising administering an agonist of the intestinal guanylate
cyclase (GC--C) receptor either orally, by rectal suppository, or
parenterally. In various embodiments: the agonist is a peptide, the
peptide includes four Cys that form two disulfide bonds, and the
peptide includes six Cys that form three disulfide bonds.
[0056] In a tenth aspect, the invention features a method for
treating a gastrointestinal disorder selected from the group
consisting of: a gastrointestinal motility disorder, irritable
bowel syndrome, chronic constipation, a functional gastrointestinal
disorder, gastroesophageal reflux disease, functional heartburn,
dyspepsia, functional dyspepsia, nonulcer dyspepsia, gastroparesis,
chronic intestinal pseudo-obstruction, colonic pseudo-obstruction,
Crohn's disease, ulcerative colitis, Inflammatory bowel disease,
the method comprising administering an agonist of the intestinal
guanylate cyclase (GC--C) receptor. In various embodiments the
composition is administered orally; the peptide comprises 30 or
fewer amino acids, the peptide comprises 20 or fewer amino acids,
and the peptide comprises no more than 5 amino acids prior to
Cys.sub.5.
[0057] In various embodiments: the agonist is a peptide, the
peptide includes four Cys that form two disulfide bonds, and the
peptide includes six Cys that form three disulfide bonds.
[0058] In an eleventh aspect, the invention features a method for
treating obesity, the method comprising administering an agonist of
the intestinal guanylate cyclase (GC--C) receptor. In various
embodiments: the agonist is a peptide, the peptide includes four
Cys that form two disulfide bonds, and the peptide includes six Cys
that form three disulfide bonds.
[0059] In a twelfth aspect, the invention features a method for
treating obesity, the method comprising administering a polypeptide
comprising the amino acid sequence: (I): Xaa.sub.1 Xaa.sub.2
Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys.sub.6 Cys.sub.7 Xaa.sub.8
Xaa.sub.9 Cys.sub.10 Cys.sub.11 Xaa.sub.12 Xaa.sub.13 Xaa.sub.14
Cys.sub.15 Xaa.sub.16 Xaa.sub.17 Cys.sub.18 Xaa.sub.19 Xaa.sub.20
Xaa.sub.21 (SEQ ID NO:119) wherein: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3
Xaa.sub.4 Xaa.sub.5 is Asn Ser Ser Asn Tyr (SEQ ID NO:121) or is
missing or Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 is missing and
Xaa.sub.5 is Asn, Trp, Tyr, Asp, Ile, Thr, or Phe; Xaa.sub.8 is
Glu, Asp, Gln, Gly or Pro; Xaa.sub.9 is Leu, Ile, Val, Ala, Lys,
Arg, Trp, Tyr or Phe; Xaa.sub.12 is Asn, Tyr, Asp or Ala;
Xaa.sub.13 is Pro or Gly; Xaa.sub.4 is Ala, Leu, Ser, Gly, Val,
Glu, Gln, Ile, Leu, Lys, Arg, and Asp; Xaa.sub.16 is Thr, Ala, Asn,
Lys, Arg, Trp; Xaa.sub.17 is Gly, Pro or Ala; Xaa.sub.19 is Trp,
Tyr, Phe or Leu; and Xaa.sub.20 Xaa.sub.21 is AspPhe or is missing
or Xaa.sub.20 is Asn or Glu and Xaa.sub.21 is missing or Xaa.sub.19
Xaa.sub.20 Xaa.sub.21 is missing. The peptide can be administered
alone or in combination with another agent for the treatment of
obesity, e.g., sibutramine or another agent, e.g., an agent
described herein.
[0060] In one embodiment the peptide comprises the amino acid
sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11
Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Cys.sub.18
Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID NO:119) wherein: Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is missing; Xaa.sub.8 is
Glu; Xaa.sub.9 is Leu, Ile, Lys, Arg, Trp, Tyr or Phe; Xaa.sub.12
is Asn; Xaa.sub.13 is Pro; Xaa.sub.14 is Ala; Xaa.sub.16 is Thr,
Ala, Lys, Arg, Trp; Xaa.sub.17 is Gly; Xaa.sub.19 is Tyr or Leu;
and Xaa.sub.20 Xaa.sub.21 is AspPhe or is missing.
[0061] In a thirteenth aspect, the invention features a
pharmaceutical composition comprising a polypeptide described
herein.
[0062] In a fourteenth aspect, the invention features a method for
treating congestive heart failure, the method comprising:
administering to the patient a composition comprising a purified
polypeptide comprising the amino acid sequence (I): Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys.sub.6 Cys.sub.7
Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11 Xaa.sub.12 Xaa.sub.13
Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17 Cys.sub.18 Xaa.sub.19
Xaa.sub.20 Xaa.sub.21 (SEQ ID NO:119) wherein: Xaa.sub.1 Xaa.sub.2
Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is Asn Ser Ser Asn Tyr (SEQ ID
NO:121) or is missing or Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 is
missing and Xaa.sub.5 is Asn, Trp, Tyr, Asp, Ile, Thr, or Phe;
Xaa.sub.8 is Glu, Asp, Gln, Gly or Pro; Xaa.sub.9 is Leu, Ile, Val,
Ala, Lys, Arg, Trp, Tyr or Phe; Xaa.sub.12 is Asn, Tyr, Asp or Ala;
Xaa.sub.13 is Pro or Gly; Xaa.sub.14 is Ala, Leu, Ser, Gly, Val,
Glu, Gln, Ile, Leu, Lys, Arg, and Asp; Xaa.sub.16 is Thr, Ala, Asn,
Lys, Arg, Trp; Xaa.sub.17 is Gly, Pro or Ala; Xaa.sub.19 is Trp,
Tyr, Phe or Leu; and Xaa.sub.20 Xaa.sub.21 is AspPhe or is missing
or Xaa.sub.20 is Asn or Glu and Xaa.sub.21 is missing or Xaa.sub.19
Xaa.sub.20 Xaa.sub.21 is missing. The peptide can be administered
in combination with another agent for treatment of congestive heart
failure, for example, a natriuretic peptide such as atrial
natriuretic peptide, brain natriuretic peptide or C-type
natriuretic peptide), a diuretic, or an inhibitor of angiotensin
converting enzyme.
[0063] In one embodiment the peptide comprises the amino acid
sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11
Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17
Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID No: 119)
wherein: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is
missing; Xaa.sub.8 is Glu; Xaa.sub.9 is Leu, Ile, Lys, Arg, Trp,
Tyr or Phe; Xaa.sub.12 is Asn; Xaa.sub.13 is Pro; Xaa.sub.14 is
Ala; Xaa.sub.16 is Thr, Ala, Lys, Arg, Trp; Xaa.sub.17 is Gly;
Xaa.sub.19 is Tyr or Leu; Xaa.sub.19 is Lys or Arg; Xaa.sub.20
Xaa.sub.21 is AspPhe or is missing.
[0064] In a fifteenth aspect, the invention features a method for
treating benign prostatic hyperplasia, the method comprising:
administering to the patient a composition comprising a purified
polypeptide comprising the amino acid sequence (I): Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys.sub.6 Cys.sub.7
Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11 Xaa.sub.12 Xaa.sub.13
Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17 Cys.sub.18 Xaa.sub.19
Xaa.sub.20 Xaa.sub.21 (SEQ ID No:119) wherein: Xaa.sub.1 Xaa.sub.2
Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is Asn Ser Ser Asn Tyr (SEQ ID
NO:121) or is missing or Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 is
missing and Xaa.sub.5 is Asn, Trp, Tyr, Asp, Ile, Thr, or Phe;
Xaa.sub.8 is Glu, Asp, Gln, Gly or Pro; Xaa.sub.9 is Leu, Ile, Val,
Ala, Lys, Arg, Trp, Tyr or Phe; Xaa.sub.12 is Asn, Tyr, Asp or Ala;
Xaa.sub.13 is Pro or Gly; Xaa.sub.14 is Ala, Leu, Ser, Gly, Val,
Glu, Gln, Ile, Leu, Lys, Arg, and Asp; Xaa.sub.16 is Thr, Ala, Asn,
Lys, Arg, Trp; Xaa.sub.17 is Gly, Pro or Ala; Xaa.sub.19 is Trp,
Tyr, Phe or Leu; Xaa.sub.19 is Lys or Arg; Xaa.sub.20 Xaa.sub.21 is
AspPhe or is missing or Xaa.sub.20 is Asn or Glu and Xaa.sub.21 is
missing or Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 is missing.
[0065] The peptide can be administered in combination with another
agent for treatment of BPH, for example, a 5-alpha reductase
inhibitor (e.g., finasteride) or an alpha adrenergic inhibitor
(e.g., doxazosine).
[0066] In one embodiment the peptide comprises the amino acid
sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11
Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17
Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 (SEQ ID No: 119)
wherein: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is
missing; Xaa.sub.8 is Glu; Xaa.sub.9 is Leu, Ile, Lys, Arg, Trp,
Tyr or Phe; Xaa.sub.12 is Asn; Xaa.sub.13 is Pro; Xaa.sub.14 is
Ala; Xaa.sub.16 is Thr, Ala, Lys, Arg, Trp; Xaa.sub.17 is Gly;
Xaa.sub.19 is Tyr or Leu; and Xaa.sub.20 Xaa.sub.21 is AspPhe or is
missing.
[0067] In a sixteenth aspect, the invention features a method for
treating or reducing pain, including visceral pain, pain associated
with a gastrointestinal disorder or pain associated with some other
disorder, the method comprising: administering to a patient a
composition comprising a is purified polypeptide comprising the
amino acid sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4
Xaa.sub.5 Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10
Cys.sub.11 Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16
Xaa.sub.17 Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21, (SEQ ID No:
119) e.g., a purified polypeptide comprising an amino acid sequence
disclosed herein.
[0068] In a seventeenth aspect, the invention features a method for
treating inflammation, including inflammation of the
gastrointestinal tract, e.g., inflammation associated with a
gastrointestinal disorder or infection or some other disorder, the
method comprising: administering to a patient a composition
comprising a purified polypeptide comprising the amino acid
sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11
Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17
Cys.sub.18 Xaa.sub.19 Xaa.sub.20 Xaa.sub.21, (SEQ ID No: 119) e.g.,
a purified polypeptide comprising an amino acid sequence disclosed
herein.
[0069] In certain embodiments the peptide includes a peptide
comprising or consisting of the amino acid sequence Xaa.sub.1
Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys Cys Glu Xaa.sub.9 Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr Xaa.sub.20 Xaa.sub.21 (II) (SEQ
ID NO:66) wherein Xaa.sub.9 is any amino acid, wherein Xaa.sub.9 is
any amino acid other than Leu, wherein Xaa.sub.9 is selected from
Phe, Trp and Tyr; wherein Xaa.sub.9 is selected from any other
natural or non-natural aromatic amino acid, wherein Xaa.sub.9 is
Tyr; wherein Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is
Asn Ser Ser Asn Tyr (SEQ ID NO:121); wherein Xaa.sub.1, Xaa.sub.2,
Xaa.sub.3, Xaa.sub.4, and Xaa.sub.5 are missing; wherein Xaa.sub.1,
Xaa.sub.2, Xaa.sub.3 and Xaa.sub.4 are missing; wherein Xaa.sub.1,
Xaa.sub.2 and Xaa.sub.3 are missing; wherein Xaa.sub.1 and
Xaa.sub.2 are missing; wherein Xaa.sub.1 is missing; wherein
Xaa.sub.20 Xaa.sub.21 is AspPhe or is missing or Xaa.sub.20 is Asn
or Glu and Xaa.sub.21 is missing or Xaa.sub.19 Xaa.sub.20
Xaa.sub.21 is missing. In the case of a peptide comprising the
sequence (I): Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5
Cys.sub.6 Cys.sub.7 Xaa.sub.8 Xaa.sub.9 Cys.sub.10 Cys.sub.11
Xaa.sub.12 Xaa.sub.13 Xaa.sub.14 Cys.sub.15 Xaa.sub.16 Xaa.sub.17
Cys.sub.18 Xaa.sub.19 Xaa.sub.20Xaa.sub.21 (SEQ ID No: 119)
wherein: Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 is
missing and/or the sequence Xaa.sub.19 Xaa.sub.20 Xaa.sub.21 is
missing peptide can still contain additional carboxyterminal or
amino terminal amino acids or both
[0070] Among the useful peptides are peptides comprising,
consisting of or consisting essentially of the amino acid sequence
Xaa.sub.1 Xaa.sub.2 Xaa.sub.3 Xaa.sub.4 Xaa.sub.5 Cys Cys Glu
Xaa.sub.9 Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Xaa.sub.20
Xaa.sub.21 (II) (SEQ ID NO:66) are the following peptides:
1 Gln Ser Ser Asn Tyr Cys Cys Glu (SEQ ID NO:67) Tyr Cys Cys Asn
Pro Ala Cys Thr Gly Cys Tyr Asn Thr Ser Asn Tyr Cys Cys Glu (SEQ ID
NO:68) Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asn Leu Ser Asn
Tyr Cys Cys Glu (SEQ ID NO:69) Tyr Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr Asn Ile Ser Asn Tyr Cys Cys Glu (SEQ ID NO:70) Tyr Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr Asn Ser Ser Gln Tyr Cys Cys Glu
(SEQ ID NO:71) Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Ser Ser
Asn Tyr Cys Cys Glu Tyr (SEQ ID NO:72) Cys Cys Asn Pro Ala Cys Thr
Gly Cys Tyr Gln Ser Ser Gln Tyr Cys Cys Glu (SEQ ID NO:73) Tyr Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr Ser Ser Gln Tyr Cys Cys Glu Tyr
(SEQ ID NO:74) Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr. Asn Ser Ser
Asn Tyr Cys Cys Glu (SEQ ID NO:75) Ala Cys Cys Asn Pro Ala Cys Thr
Gly Cys Tyr Asn Ser Ser Asn Tyr Cys Cys Glu (SEQ ID NO:76) Arg Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asn Ser Ser Asn Tyr Cys Cys Glu
(SEQ ID NO:77) Asn Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asn Ser
Ser Asn Tyr Cys Cys Glu (SEQ ID NO:78) Asp Cys Cys Asn Pro Ala Cys
Thr Gly Cys Tyr Asn Ser Ser Asn Tyr Cys Cys Glu (SEQ ID NO:79) Cys
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asn Ser Ser Asn Tyr Cys Cys
Glu (SEQ ID NO:80) Gln Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asn
Ser Ser Asn Tyr Cys Cys Glu (SEQ ID NO:81) Glu Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr Asn Ser Ser Asn Tyr Cys Cys Glu (SEQ ID NO:82)
Gly Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asn Ser Ser Asn Tyr Cys
Cys Glu (SEQ ID NO:83) His Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
Asn Ser Ser Asn Tyr Cys Cys Glu (SEQ ID NO:84) Ile Cys Cys Asn Pro
Ala Cys Thr Gly Cys Tyr Asn Ser Ser Asn Tyr Cys Cys Glu (SEQ ID
NO:85) Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asn Ser Ser Asn
Tyr Cys Cys Glu (SEQ ID NO:86) Met Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr Asn Ser Ser Asn Tyr Cys Cys Glu (SEQ ID NO:87) Phe Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr Asn Ser Ser Asn Tyr Cys Cys Glu
(SEQ ID NO:88) Pro Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asn Ser
Ser Asn Tyr Cys Cys Glu (SEQ ID NO:89) Ser Cys Cys Asn Pro Ala Cys
Thr Gly Cys Tyr Asn Ser Ser Asn Tyr Cys Cys Glu (SEQ ID NO:90) Thr
Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asn Ser Ser Asn Tyr Cys Cys
Glu (SEQ ID NO:91 Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asn
Ser Ser Asn Tyr Cys Cys Glu (SEQ ID NO:92) Val Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr Cys Cys Glu Ala Cys Cys Asn Pro (SEQ ID NO:93)
Ala Cys Thr Gly Cys Tyr Cys Cys Glu Arg Cys Cys Asn Pro (SEQ ID
NO:94) Ala Cys Thr Gly Cys Tyr Cys Cys Glu Asn Cys Cys Asn Pro (SEQ
ID NO:95) Ala Cys Thr Gly Cys Tyr Cys Cys Glu Asp Cys Cys Asn Pro
(SEQ ID NO:96) Ala Cys Thr Gly Cys Tyr Cys Cys Glu Cys Cys Cys Asn
Pro (SEQ ID NO:97) Ala Cys Thr Gly Cys Tyr Cys Cys Glu Gln Cys Cys
Asn Pro (SEQ ID NO:98) Ala Cys Thr Gly Cys Tyr Cys Cys Glu Glu Cys
Cys Asn Pro (SEQ ID NO:99) Ala Cys Thr Gly Cys Tyr Cys Cys Glu Gly
Cys Cys Asn Pro (SEQ ID NO:100) Ala Cys Thr Gly Cys Tyr Cys Cys Glu
His Cys Cys Asn Pro (SEQ ID NO:101) Ala Cys Thr Gly Cys Tyr Cys Cys
Glu Ile Cys Cys Asn Pro (SEQ ID NO:102) Ala Cys Thr Gly Cys Tyr Cys
Cys Glu Lys Cys Cys Asn Pro (SEQ ID NO:103) Ala Cys Thr Gly Cys Tyr
Cys Cys Glu Met Cys Cys Asn Pro (SEQ ID NO:104) Ala Cys Thr Gly Cys
Tyr Cys Cys Glu Phe Cys Cys Asn Pro (SEQ ID NO:105) Ala Cys Thr Gly
Cys Tyr Cys Cys Glu Pro Cys Cys Asn Pro (SEQ ID NO:106) Ala Cys Thr
Gly Cys Tyr Cys Cys Glu Ser Cys Cys Asn Pro (SEQ ID NO:107) Ala Cys
Thr Gly Cys Tyr Cys Cys Glu Thr Cys Cys Asn Pro (SEQ ID NO:108) Ala
Cys Thr Gly Cys Tyr Cys Cys Glu Trp Cys Cys Asn Pro (SEQ ID NO:109)
Ala Cys Thr Gly Cys Tyr Cys Cys Glu Val Cys Cys Asn Pro (SEQ ID
NO:110) Ala Cys Thr Gly Cys Tyr
[0071] In an eighteenth aspect, the invention features a method for
treating congestive heart failure, the method comprising
administering a complete or partial agonist of the intestinal
guanylate cyclase (GC--C) receptor. The agonist can be administered
in combination with another agent for treatment of congestive heart
failure, for example, a natriuretic peptide such as atrial
natriuretic peptide, brain natriuretic peptide or C-type
natriuretic peptide), a diuretic, or an inhibitor of angiotensin
converting enzyme.
[0072] In a nineteenth aspect, the invention features a method for
treating BPH, the method comprising administering a complete or
partial agonist of the intestinal guanylate cyclase (GC--C)
receptor. The agonist can be administered in combination with
another agent for treatment of BPH, for example, a 5-alpha
reductase inhibitor (e.g., finasteride) or an alpha adrenergic
inhibitor (e.g., doxazosine).
[0073] In a twentieth aspect, the invention features a method for
treating obesity, the method comprising administering a complete or
partial agonist of the intestinal guanylate cyclase (GC--C)
receptor. The agonist can be administered in combination with
another agent for treatment of obesity, for example, gut hormone
fragment peptide YY.sub.3-36 (PYY.sub.3-36)(N. Engl. J. Med.
349:941, 2003; ikpeapge daspeelnry yaslrhylnl vtrqry) glp-1
(glucagon-like peptide-1), exendin-4 (an inhibitor of glp-1),
sibutramine, phentermine, phendimetrazine, benzphetamine
hydrochloride (Didrex), orlistat (Xenical), diethylpropion
hydrochloride (Tenuate), fluoxetine (Prozac), bupropion, ephedra,
chromium, garcinia cambogia, benzocaine, bladderwrack (focus
vesiculosus), chitosan, nomame herba, galega (Goat's Rue, French
Lilac), conjugated linoleic acid, L-carnitine, fiber (psyllium,
plantago, guar fiber), caffeine, dehydroepiandrosterone, germander
(teucrium chamaedrys), B-hydroxy-.beta.-methylbutyrate, and
pyruvate. A peptide useful for treating obesity can be administered
as a co-therapy with a peptide of the invention either as a
distinct molecule or as part of a fusion protein with a peptide of
the invention. Thus, for example, PYY.sub.3-36 can be fused to the
carboxy or amino terminus of a peptide of the invention. Such a
fusion protein can include a chymostrypsin or trypsin cleavage site
that can permit cleavage to separate the two peptides.
[0074] The peptides and agonist of the intestinal guanylate cyclase
(GC--C) receptor can be used to treat constipation or decreased
intestinal motility, slow digestion or slow stomach emptying. The
peptides can be used to relieve one or more symptoms of IBS
(bloating, pain, constipation), GERD (acid reflux into the
esophagus), functional dyspepsia, or gastroparesis (nausea,
vomiting, bloating, delayed gastric emptying) and other disorders
described herein.
[0075] The details of one or more embodiments of the invention are
set forth in the accompanying description. All of the publications,
patents and patnet applications are hereby incorporated by
reference.
FIGURES
[0076] FIG. 1a depicts the results of LCMS analysis of recombinant
MM-416776 peptide and MD-915 peptide.
[0077] FIGS. 1b and c depict the results of LCMS analysis of
synthetic MD-1100 peptide and the blank.
[0078] FIG. 2 depicts the results of the intestinal GC--C receptor
activity assay of synthetic MM-416776 peptide, MD-915 peptide and
two different MD-1100 peptides.
[0079] FIG. 3a depicts the effect of recombinant MM-416776 peptide
and Zelnorm.RTM. in a murine gastrointestinal transit model.
[0080] FIG. 3b depicts the effect of synthetic MD-1100 peptide and
Zelnorm.RTM. in an acute murine gastrointestinal transit model.
[0081] FIG. 3b depicts the effect of synthetic MD-1100 peptide and
Zelnorm.RTM. in an chronic murine gastrointestinal transit
model.
[0082] FIGS. 4a and 4b depict the effect of peptides MD-915,
MD-1100, and MM-416776 in an acute murine gastrointestinal transit
model.
[0083] FIG. 4c depicts the effect of MD-1100 peptide in a chronic
murine gastrointestinal transit model.
[0084] FIG. 5a depicts the effect of MM-416776 peptide and
Zelnorm.RTM. in a suckling mouse intestinal secretion model.
[0085] FIG. 5b depicts the effects of MD-1100 and Zelnorm.RTM. in a
mouse intestinal secretion model.
[0086] FIGS. 6a and 6b depict the effects of MM 416776, MD-1100 and
MD-915 peptides in a mouse intestinal secretion model.
[0087] FIG. 7 shows the results of experiment in which MD-1100
activity was analyzed in the TNBS colonic distention model.
[0088] FIGS. 8a and 8b show the effects of differing doses of
MD-915 and MD-1100 in the PBQ writhing assay.
[0089] FIG. 9 shows the results of Kd determination analysis using
MD-1100 in a competitive radioligand binding assay.
[0090] FIGS. 10a and 10b show bioavailability data for IV and
orally administered MD-1100 as detected by an ELISA assay and
LCMS.
DETAILED DESCRIPTION
[0091] The peptides of the invention bind to the intestinal
guanylate cyclase (GC--C) receptor, a key regulator of fluid and
electrolyte balance in the intestine. When stimulated, this
receptor, which is located on the apical membrane of the intestinal
epithelial surface, causes an increase in intestinal epithelial
cyclic GMP (cGMP). This increase in cGMP is believed to cause a
decrease in water and sodium absorption and an increase in chloride
and potassium ion secretion, leading to changes in intestinal fluid
and electrolyte transport and increased intestinal motility. The
intestinal GC--C receptor possesses an extracellular ligand binding
region, a transmembrane region, an intracellular protein
kinase-like region and a cyclase catalytic domain. Proposed
functions for the GC--C receptor are fluid and electrolyte
homeostasis, the regulation of epithelial cell proliferation and
the induction of apoptosis (Shalubhai 2002 Curr Opin Drug Dis Devel
5:261-268).
[0092] In addition to being expressed in the intestine by
gastrointestinal epithelial cells, GC--C is expressed in
extra-intestinal tissues including kidney, lung, pancreas,
pituitary, adrenal, developing liver (reviewed in Vaandrager 2002,
Mol Cell Biochem 230:73-83) and male and female reproductive
tissues (reviewed in Vaandrager 2002 Mol Cell Biochem 230:73-83))
This suggests that the GC--C receptor agonists can be used in the
treatment of disorders outside the GI tract, for example,
congestive heart failure and benign prostatic hyperplasia.
[0093] Ghrelin, a peptide hormone secreted by the stomach, is a key
regulator of appetite in humans. Ghrelin expression levels are
regulated by fasting and by gastric emptying (Kim et al., 2003,
Neuroreprt 14:1317-20; Gualillo et al., 2003, FEBS Letts 552:
105-9). Thus, by increasing gastrointestinal motility, GC--C
receptor agonists may also be used to regulate obesity.
[0094] In humans, the GC--C receptor is activated by guanylin (Gn)
(U.S. Pat. No. 5,96,097), uroguanylin (Ugn) (U.S. Pat. No.
5,140,102) and lymphoguanylin (Forte et al., 1999, Endocrinology
140:1800-1806). Interestingly, these agents are 10-100 fold less
potent than a class of bacterially derived peptides, termed ST
(reviewed in Gianella 1995 J Lab Clin Med 125:173-181). ST peptides
are considered super agonists of GC--C and are very resistant to
proteolytic degradation.
[0095] ST peptide is capable of stimulating the enteric nervous
system (Rolfe et al., 1994, J Physiolo 475: 531-537; Rolfe et al.,
1999, Gut 44: 615-619; Nzegwu et al., 1996, Exp Physiol 81:
313-315). Also, cGMP has been reported to have anitnociceptive
effects in multiple animal models of pain (Lazaro Ibanez et al.,
2001, Eur J Pharmacol 426: 39-44; Soares et al., 2001, British J
Pharmacol 134: 127-131; Jain et al., 2001, Brain Res 909:170-178;
Amarante et al., 2002, Eur J Pharmacol 454:19-23). Thus, GC--C
agonists may have both an analgesic as well an anti-inflammatory
effect.
[0096] In bacteria, ST peptides are derived from a preproprotein
that generally has at least 70 amino acids. The pre and pro regions
are cleaved as part of the secretion process, and the resulting
mature protein, which generally includes fewer than 20 amino acids,
is biologically active.
[0097] Among the known bacterial ST peptides are: E. coli ST Ib
(Moseley et al. (1983) Infect. Immun. 39:1167) having the mature
amino acid sequence Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys Cys Asn
Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:1); E. coli ST Ia (So and
McCarthy (1980) Proc. Natl. Acad. Sci. USA 77:4011) having the
mature amino acid sequence Asn Thr Phe Tyr Cys Cys Glu Leu Cys Cys
Asn Pro Ala Cys Ala Gly Cys Tyr (SEQ ID NO:2); E. coli ST I* (Chan
and Giannella (1981) J. Biol. Chem. 256:7744) having the mature
amino acid sequence Asn Thr Phe Tyr Cys Cys Glu Leu Cys Cys Tyr Pro
Ala Cys Ala Gly Cys Asn (SEQ ID NO:3); C.freundii ST peptide
(Guarino et al. (1989) Infect. Immun. 57:649) having the mature
amino acid sequence Asn Thr Phe Tyr Cys Cys Glu Leu Cys Cys Asn Pro
Ala Cys Ala Gly Cys Tyr (SEQ ID NO:4); Y. enterocolitica ST
peptides, Y-ST(Y-STa), Y-STb, and Y-STc (reviewed in Huang et al.
(1997) Microb. Pathog. 22:89) having the following pro-form amino
acid sequences: Gln Ala Cys Asp Pro Pro Ser Pro Pro Ala Glu Val Ser
Ser Asp Trp Asp Cys Cys Asp Val Cys Cys Asn Pro Ala Cys Ala Gly Cys
(SEQ ID NO:5) (as well as a Ser-7 to Leu-7 variant of Y-STa (SEQ ID
NO:122), (Takao et al. (1985) Eur. J. Biochem. 152:199)); Lys Ala
Cys Asp Thr Gln Thr Pro Ser Pro Ser Glu Glu Asn Asp Asp Trp Cys Cys
Glu Val Cys Cys Asn Pro Ala Cys Ala Gly Cys (SEQ ID NO:6); Gln Glu
Thr Ala Ser Gly Gln Val Gly Asp Val Ser Ser Ser Thr Ile Ala Thr Glu
Val Ser Glu Ala Glu Cys Gly Thr Gln Ser Ala Thr Thr Gln Gly Glu Asn
Asp Trp Asp Trp Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Phe Gly Cys
(SEQ ID NO:7), respectively; Y. kristensenii ST peptide having the
mature amino acid sequence Ser Asp Trp Cys Cys Glu Val Cys Cys Asn
Pro Ala Cys Ala Gly Cys (SEQ ID NO:8); V. cholerae non-01 ST
peptide (Takao et al. (1985) FEBS lett. 193:250) having the mature
amino acid sequence Ile Asp Cys Cys Glu Ile Cys Cys Asn Pro Ala Cys
Phe Gly Cys Leu Asn (SEQ ID NO:9); and V. mimicus ST peptide (Arita
(1991) et al. FEMS Microbiol. Lett. 79:105) having the mature amino
acid sequence Ile Asp Cys Cys Glu Ile Cys Cys Asn Pro Ala Cys Phe
Gly Cys Leu Asn (SEQ ID NO:10). The Table below provides sequences
of all or a portion of a number of mature ST peptides.
2 Gen- Bank .RTM. Gen- Acces- Bank .RTM. sion GI Sequence QHECIB
69638 NSSNYCCELCCNPACTGCY (SEQ ID NO:1) P01559 123711
NTFYCCELCCNPACAGCY (SEQ ID NO:2) AAA24653 147878 NTFYCCELCCNPACAPCY
(SEQ ID NO:11) P01560 123707 NTFYCCELCCYPACAGCN (SEQ ID NO:3)
AAA27561 295439 IDCCEICCNPACFGCLN (SEQ ID NO:9) P04429 123712
IDCCEICCNPACFGCLN (SEQ ID NO:10) S34671 421286 IDCCEICCNPACF (SEQ
ID NO:12) CAA52209 395161 IDCCEICCNPACFG (SEQ ID NO:13) A54534
628844 IDCCEICCNPACFGCLN (SEQ ID NO:14) AAL02159 15592919
IDRCEICCNPACFGCLN (SEQ ID NO:15) AAA18472 487395 DWDCCDVCCNPACAGC
(SEQ ID NO:16) S25659 282047 DWDCCDVCCNPACAGC (SEQ ID NO:17) P74977
3913874 NDDWCCEVCCNPACAGC (SEQ ID NO:18) BAA23656 2662339
WDWCCELCCNPACFGC (SEQ ID NO:19) P31518 399947 SDWCCEVCCNPACAGC (SEQ
ID NO:8)
[0098] The immature (including pre and pro regions) form of E. coli
ST-1A (ST-P) protein has the sequence:
mkklmlaifisvlsfpsfsqstesldsskekitletkkcd-
vvknnsekksenmnntfyccelccnpacagcy (SEQ ID NO:20; see GenBank.RTM.
Accession No. P01559 (gi:123711). The pre sequence extends from aa
1-19. The pro sequence extends from aa 20-54. The mature protein
extends from 55-72. The immature (including pre and pro regions)
form of E. coli ST-1B (ST-H) protein has the sequence:
mkksilfiflsvlsfspfaqdakpvesskekitleskkcniakksnk-
sgpesmnssnyccelccnpactgcy (SEQ ID NO: 21; see GenBank.RTM.
Accession No. P07965 (gi:3915589). The immature (including pre and
pro regions) form of Y. enterocolitica ST protein has the sequence:
mkkivfvlvlmlssfgafgqetvsgq-
fsdalstpitaevykqacdpplppaevssdwdccdvccnpacagc (SEQ ID NO:22) see
GenBank.RTM. Accession No. S25659 (gi:282047).
[0099] The peptides of the invention, like the bacterial ST
peptides, have six Cys residues. These six Cys residues form three
disulfide bonds in the mature and active form of the peptide. If
the six Cys residues are identified, from the amino to carboxy
terminus of the peptide, as A, B, C, D, E, and F, then the
disulfide bonds form as follows: A-D, B-E, and C--F. The formation
of these bonds is thought to be important for GC--C receptor
binding. Certain of the peptides of the invention include a
potentially functional chymotrypsin cleavage site, e.g., a Trp, Tyr
or Phe located between either Cys B and Cys D or between Cys E and
Cys F. Cleavage at either chymotrypsin cleavage site reduces or
eliminates the ability of the peptide to bind to the GC--C
receptor.
[0100] In the human body an inactive form of chymotrypsin,
chymotrypsinogen is produced in the pancreas. When this inactive
enzyme reaches the small intestine it is converted to active
chymotrypsin by the excision of two di-peptides. Active
chymotrypsin can potentially cleave peptides at the peptide bond on
the carboxy-terminal side of Trp, Tyr or Phe. The presence of
active chymotrypsin in the intestinal tract can potentially lead to
cleavage of certain of the peptides of the invention having an
appropriately positioned functional chymotrypsin cleavage site. It
is expected that chymotrypsin cleavage will moderate the action of
a peptide of the invention having an appropriately positioned
chymotrypsin cleavage site as the peptide passes through the
intestinal tract.
[0101] Trypsinogen, like chymotrypsin, is a serine protease that is
produced in the pancreas and is present in the digestive tract. The
active form, trypsin, will cleave peptides having a Lys or Arg. The
presence of active trypsin in the intestinal tract can lead to
cleavage of certain of the peptides of the invention having an
appropriately positioned functional trypsin cleavage site. It is
expected that chymotrypsin cleavage will moderate the action of a
peptide of the invention having an appropriately positioned trypsin
cleavage site as the peptide passes through the intestinal
tract.
[0102] Many gastrointestinal disorders, including IBS, are
associated with abdominal or visceral pain. Certain of the peptides
of the invention include analgesic or antinociceptive tags such as
the carboxy-terminal sequence AspPhe immediately following a Trp,
Tyr or Phe that creates a functional chymotrypsin cleavage site or
following Lys or Arg that creates a functional trypsin cleavage
site. Chymotrypsin in the intestinal tract can potentially cleave
such peptides immediately carboxy terminal to the Trp, Phe or Tyr
residue, releasing the dipeptide, AspPhe. This dipeptide has been
shown to have analgesic activity in animal models (Abdikkahi et al.
2001, Fundam Clin Pharmacol 15:117-23; Nikfar et al 1997, 29:583-6;
Edmundson et al 1998, Clin Pharmacol Ther 63:580-93). In this
manner such peptides can treat both pain and inflammation. Other
analgesic peptides can be present at the carboxy terminus of the
peptide (following a functional cleavage site) including:
endomorphin-1, endomorphin-2, nocistatin, dalargin, lupron, and
substance P. A number of the useful peptides are based on the core
sequence: Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO:29). To create a variant having a potentially functional
chymotrypsin cleavage site capable of inactivating the peptide,
either the Leu (underlined) or the Thr (underlined) can be replaced
by Trp, Phe or Tyr or both the Leu and the Thr can be replaced by
(independently) Trp, Phe or Tyr. To create a variant having an
analgesic di-peptide, the core sequence is followed by Asp Phe. The
carboxy terminal Tyr in the core sequence can allow the Asp Phe
dipeptide to be released by chymotrypsin in the digestive tract.
The core sequence can be optionally be preceded by Asn Ser Ser Asn
Tyr or Asn.
[0103] Thus, useful variants based on the core sequence
include:
3 Asn Ser Ser Asn Tyr Cys Cys Glu (SEQ ID NO:26; Leu Cys Cys Asn
Pro Ala Cys Thr MM-416776) Gly Cys Tyr Asn Ser Ser Asn Tyr Cys Cys
Glu (SEQ ID NO:27) Leu Cys Cys Asn Pro Ala Cys Trp Gly Cys Tyr Asn
Ser Ser Asn Tyr Cys Cys Glu (SEQ ID NO:28; Tyr Cys Cys Asn Pro Ala
Cys Thr MD-915) Gly Cys Tyr Cys Cys Glu Leu Cys Cys Asn Pro (SEQ ID
NO:29; Ala Cys Thr Gly Cys Tyr MM416774) Cys Cys Glu Leu Cys Cys
Asn Pro (SEQ ID NO:30) Ala Cys Trp Gly Cys Tyr Cys Cys Glu Tyr Cys
Cys Asn Pro (SEQ ID NO:31; Ala Cys Thr Gly Cys Tyr MD-1100) Asn Cys
Cys Glu Leu Cys Cys Asn (SEQ ID NO:32) Pro Ala Cys Thr Gly Cys Tyr
Asn Cys Cys Glu Leu Cys Cys Asn (SEQ ID NO:33) Pro Ala Cys Trp Gly
Cys Tyr Asn Cys Cys Glu Phe Cys Cys Asn (SEQ ID NO:34) Pro Ala Cys
Thr Gly Cys Tyr Asn Cys Cys Glu Tyr Cys Cys Asn (SEQ ID NO:35) Pro
Ala Cys Thr Gly Cys Tyr Asn Cys Cys Glu Trp Cys Cys Asn (SEQ ID
NO:36) Pro Ala Cys Thr Gly Cys Tyr Asn Cys Cys Glu Arg Cys Cys Asn
(SEQ ID NO:37) Pro Ala Cys Thr Gly Cys Tyr Asn Cys Cys Glu Lys Cys
Cys Asn (SEQ ID NO:38) Pro Ala Cys Thr Gly Cys Tyr Asn Ser Ser Asn
Tyr Cys Cys Glu (SEQ ID NO:39) Leu Cys Cys Asn Pro Ala Cys Thr Gly
Cys Tyr Asp Phe Asn Ser Ser Asn Tyr Cys Cys Glu (SEQ ID NO:40) Leu
Cys Cys Asn Pro Ala Cys Trp Gly Cys Tyr Asp Phe Asn Ser Ser Asn Tyr
Cys Cys Glu (SEQ ID NO:41) Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys
Tyr Asp Phe Asn Ser Ser Asn Tyr Cys Cys Glu (SEQ ID NO:42) Tyr Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe Asn Ser Ser Asn Tyr Cys
Cys Glu (SEQ ID NO:43) Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
Asp Phe Asn Ser Ser Asn Tyr Cys Cys Glu (SEQ ID NO:44) Arg Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe Asn Ser Ser Asn Tyr Cys Cys
Glu (SEQ ID NO:45) Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp
Phe Cys Cys Glu Leu Cys Cys Asn Pro (SEQ ID NO:46) Ala Cys Thr Gly
Cys Tyr Asp Phe Cys Cys Glu Leu Cys Cys Asn Pro (SEQ ID NO:47) Ala
Cys Trp Gly Cys Tyr Asp Phe Cys Cys Glu Phe Cys Cys Asn Pro (SEQ ID
NO:48) Ala Cys Thr Gly Cys Tyr Asp Phe Cys Cys Glu Tyr Cys Cys Asn
Pro (SEQ ID NO:49) Ala Cys Thr Gly Cys Tyr Asp Phe Cys Cys Glu Trp
Cys Cys Asn Pro (SEQ ID NO:50) Ala Cys Thr Gly Cys Tyr Asp Phe Cys
Cys Glu Arg Cys Cys Asn Pro (SEQ ID NO:51) Ala Cys Thr Gly Cys Tyr
Asp Phe Cys Cys Glu Lys Cys Cys Asn Pro (SEQ ID NO:52) Ala Cys Thr
Gly Cys Tyr Asp Phe Asn Cys Cys Glu Leu Cys Cys Asn (SEQ ID NO:53)
Pro Ala Cys Thr Gly Cys Tyr Asp Phe Asn Cys Cys Glu Leu Cys Cys Asn
(SEQ ID NO:54) Pro Ala Cys Trp Gly Cys Tyr Asp Phe Asn Cys Cys Glu
Phe Cys Cys Asn (SEQ ID NO:55) Pro Ala Cys Thr Gly Cys Tyr Asp Phe
Asn Cys Cys Glu Tyr Cys Cys Asn (SEQ ID NO:56) Pro Ala Cys Thr Gly
Cys Tyr Asp Phe Asn Cys Cys Glu Trp Cys Cys Asn (SEQ ID NO:57) Pro
Ala Cys Thr Gly Cys Tyr Asp Phe Asn Cys Cys Glu Arg Cys Cys Asn
(SEQ ID NO:58) Pro Ala Cys Thr Gly Cys Tyr Asp Phe Asn Cys Cys Glu
Lys Cys Cys Asn (SEQ ID NO:59) Pro Ala Cys Thr Gly Cys Tyr Asp
Phe
[0104] In some cases, the peptides of the invention are produced as
a prepro protein that includes the amino terminal leader sequence:
mkksilfiflsvlsfspfaqdakpvesskekitleskkcniakksnksgpesmn (SEQ ID
NO:23). Where the peptide is produced by a bacterial cell, e.g., E.
coli, the forgoing leader sequence will be cleaved and the mature
peptide will be efficiently secreted from the bacterial cell. U.S.
Pat. No. 5,395,490 describes vectors, expression systems and
methods for the efficient production of ST peptides in bacterial
cells and methods for achieving efficient secretion of mature ST
peptides. The vectors, expression systems and methods described in
U.S. Pat. No. 5,395,490 can be used to produce the ST peptides and
variant ST peptides of the present invention
[0105] Variant Peptides
[0106] The invention includes variant peptides which can include
one, two, three, four, five, six, seven, eight, nine, or ten (in
some embodiments fewer than 5 or fewer than 3 or 2 or fewer) amino
acid substitutions compared to SEQ ID NOs:25 to 59 and 66 to 110.
The substitution(s) can be conservative or non-conservative. The
naturally-occurring amino acids can be substituted by D-isomers of
any amino acid, non-natural amino acids, and other groups. A
conservative amino acid substitution results in the alteration of
an amino acid for a similar acting amino acid, or amino acid of
like charge, polarity, or hydrophobicity. At some positions, even
conservative amino acid substitutions can reduce the activity of
the peptide. Among the naturally occurring amino acid substitutions
generally considered conservative are:
4 For Amino Acid Code Replace with any of Alanine Ala Gly, Cys, Ser
Arginine Arg Lys, His Asparagine Asn Asp, Glu, Gln, Aspartic Acid
Asp Asn, Glu, Gln Cysteine Cys Met, Thr, Ser Glutamine Gln Asn,
Glu, Asp Glutamic Acid Glu Asp, Asn, Gln Glycine Gly Ala Histidine
His Lys, Arg Isoleucine Ile Val, Leu, Met Leucine Leu Val, Ile, Met
Lysine Lys Arg, His Methionine Met Ile, Leu, Val Phenylalanine Phe
Tyr, His, Trp Proline Pro Serine Ser Thr, Cys, Ala Threonine Thr
Ser, Met, Val Tryptophan Trp Phe, Tyr Tyrosine Tyr Phe, His Valine
Val Leu, Ile, Met
[0107] In some circumstances it can be desirable to treat patients
with a variant peptide that binds to and activates intestinal GC--C
receptor, but is less active than the non-variant form the peptide.
This reduced activity can arise from reduced affinity for the
receptor or a reduced ability to activate the receptor once bound
or reduced stability of the peptide.
[0108] In some peptides pairs of Cys residues which normally form a
disulfide bond one or both members of the pair can be replaced by
homocysteine, 3-mercaptoproline (Kolodziej et al. 1996 Int J Pept
Protein Res 48:274); .beta., .beta. dimethylcysteine (Hunt et al.
1993 Int J Pept Protein Res 42:249) or diaminopropionic acid (Smith
et al. 1978 J Med Chem 21:117) to form alternative internal
cross-links at the positions of the normal disulfide bonds.
[0109] Production of Peptides
[0110] Useful peptides can be produced either in bacteria
including, without limitation, E. coli, or in other existing
systems for peptide or protein production (e.g., Bacillus subtilis,
baculovirus expression systems using Drosophila Sf9 cells, yeast or
filamentous fungal expression systems, mammalian cell expression
systems), or they can be chemically synthesized.
[0111] If the peptide or variant peptide is to be produced in
bacteria, e.g., E. coli, the nucleic acid molecule encoding the
peptide will preferably also encode a leader sequence that permits
the secretion of the mature peptide from the cell. Thus, the
sequence encoding the peptide can include the pre sequence and the
pro sequence of, for example, a naturally-occurring bacterial ST
peptide. The secreted, mature peptide can be purified from the
culture medium.
[0112] The sequence encoding a peptide of the invention is
preferably inserted into a vector capable of delivering and
maintaining the nucleic acid molecule in a bacterial cell. The DNA
molecule may be inserted into an autonomously replicating vector
(suitable vectors include, for example, pGEM3Z and pcDNA3, and
derivatives thereof). The vector nucleic acid may be a bacterial or
bacteriophage DNA such as bacteriophage lambda or M13 and
derivatives thereof. Construction of a vector containing a nucleic
acid described herein can be followed by transformation of a host
cell such as a bacterium. Suitable bacterial hosts include but are
not limited to, E. coli, B. subtilis, Pseudomonas, Salmonella. The
genetic construct also includes, in addition to the encoding
nucleic acid molecule, elements that allow expression, such as a
promoter and regulatory sequences. The expression vectors may
contain transcriptional control sequences that control
transcriptional initiation, such as promoter, enhancer, operator,
and repressor sequences. A variety of transcriptional control
sequences are well known to those in the art. The expression vector
can also include a translation regulatory sequence (e.g., an
untranslated 5' sequence, an untranslated 3' sequence, or an
internal ribosome entry site). The vector can be capable of
autonomous replication or it can integrate into host DNA to ensure
stability during peptide production.
[0113] The protein coding sequence that includes a peptide of the
invention can also be fused to a nucleic acid encoding a
polypeptide affinity tag, e.g., glutathione S-transferase (GST),
maltose E binding protein, protein A, FLAG tag, hexa-histidine, myc
tag or the influenza HA tag, in order to facilitate purification.
The affinity tag or reporter fusion joins the reading frame of the
peptide of interest to the reading frame of the gene encoding the
affinity tag such that a translational fusion is generated.
Expression of the fusion gene results in translation of a single
polypeptide that includes both the peptide of interest and the
affinity tag. In some instances where affinity tags are utilized,
DNA sequence encoding a protease recognition site will be fused
between the reading frames for the affinity tag and the peptide of
interest.
[0114] Genetic constructs and methods suitable for production of
immature and mature forms of the peptides and variants of the
invention in protein expression systems other than bacteria, and
well known to those skilled in the art, can also be used to produce
peptides in a biological system.
[0115] Mature peptides and variants thereof can be synthesized by
the solid-phase method using an automated peptide synthesizer. For
example, the peptide can be synthesized on
Cyc(4-CH.sub.2Bxl)-OCH.sub.2-4-(oxymeth- yl)-phenylacetamidomethyl
resin using a double coupling program. Protecting groups must be
used appropriately to create the correct disulfide bond pattern.
For example, the following protecting groups can be used:
t-butyloxycarbonyl (alpha-amino groups); acetamidomethyl (thiol
groups of Cys residues B and E); 4-methylbenyl (thiol groups of Cys
residues C and F); benzyl (y-carboxyl of glutamic acid and the
hydroxyl group of threonine, if present); and bromobenzyl (phenolic
group of tyrosine, if present). Coupling is effected with
symmetrical anhydride of t-butoxylcarbonylamino acids or
hydroxybenzotriazole ester (for asparagine or glutamine residues),
and the peptide is deprotected and cleaved from the solid support
in hydrogen fluoride, dimethyl sulfide, anisole, and p-thiocresol
using 8/1/1/0.5 ratio (v/v/v/w) at 0.degree. C. for 60 min. After
removal of hydrogen fluoride and dimethyl sulfide by reduced
pressure and anisole and p-thiocresol by extraction with ethyl
ether and ethyl acetate sequentially, crude peptides are extracted
with a mixture of 0.5M sodium phosphate buffer, pH 8.0 and
N,N-dimethylformamide using 1/1 ratio, v/v. The disulfide bond for
Cys residues B and E is the formed using dimethyl sulfoxide (Tam et
al. (1991) J. Am. Chem. Soc. 113:6657-62). The resulting peptide is
the purified by reverse-phase chromatography. The disulfide bond
between Cys residues C and F is formed by first dissolving the
peptide in 50% acetic acid in water. Saturated iodine solution in
glacial acetic acid is added (1 ml iodine solution per 100 ml
solution). After incubation at room temperature for 2 days in an
enclosed glass container, the solution is diluted five-fold with
deionized water and extracted with ethyl ether four times for
removal of unreacted iodine. After removal of the residual amount
of ethyl ether by rotary evaporation the solution of crude product
is lyophilized and purified by successive reverse-phase
chromatography.
[0116] Intestinal GC--C Receptor Binding Assay
[0117] The ability of peptides and other agents to bind to the
intestinal GC--C receptor can be tested as follows. Cells of the
T84 human colon carcinoma cell line (American Type Culture
Collection (Bethesda, Md.) are grown to confluence in 24-well
culture plates with a 1:1 mixture of Ham's F12 medium and
Dulbecco's modified Eagle's medium (DMEM), supplemented with 5%
fetal calf serum. Cells used in the assay are typically between
passages 54-60. Briefly, T84 cell monolayers in 24-well plates are
washed twice with 1 ml of binding buffer (DMEM containing 0.05%
bovine serum albumin and 25 mM HEPES, pH 7.2), then incubated for
30 min at 37.degree. C. in the presence of mature radioactively
labeled E. coli ST peptide and the test material at various
concentrations. The cells are then washed four times with 1 ml of
DMEM and solubilized with 0.5 ml/well 1N NaOH. The level of
radioactivity in the solubilized material is then determined using
standard methods.
EXAMPLE 1
Preparation of Variant ST Peptides and Wild-Type ST Peptide
1a: Preparation of Recombinant Variant ST Peptides and Wild-Type ST
Peptide
[0118] A variant ST peptide, referred to as MD-915, was reproduced
recombinantly and tested in an animal model. MD-915 has the
sequence: Asn Ser Ser Asn Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala
Cys Thr Gly Cys Tyr (SEQ ID NO:28). A peptide having the sequence
of the wild-type ST peptide was also created (MM-416776). MD-915
and MM-416776 peptides were produced as preproproteins using
vectors produced as follows. A sequence encoding a heat-stable
enterotoxin pre-pro sequence was amplified from pGK51/pGSK51 (ATCC
67728) using oligonucleotide MO3514
(5'CACACCATATGAAGAAATCAATATTATTTATTTTTCTTTCTG 3' (SEG ID NO:60))
and oligonucelotide M03515
(5'CACACCTCGAGTTAGGTCTCCATGCTTTCAGGACCACTTTTATTAC 3' (SEQ ID NO:
61)). The amplification product fragment was digested with
NdeI/XhoI and ligated to the T7 expression vector, pET26b(+)
(Novagen) digested with NdeI/XhoI thereby creating plasmid MB3976.
The region encoding the pre-pro protein was sequenced and found to
encode the amino acid sequence:
mkksilfiflsvlsfspfaqdakpagsskekitleskkcnivkksnksgpesm (SEQ ID NO:
24) which differs from the amino acid sequence of heat-stable
enterotoxin a2 precursor (sta2;
mkksilfiflsvlsfspfaqdakpagsskekitleskkcni- vkknnesspesm (SEQ ID
NO:25); GenBank.RTM. Accession No. Q47185, GI: 3913876) at three
positions (indicated by underlining and bold text) near the
C-terminus. To create expression vectors with the pre-pro sequence,
complementary oligos encoding each ST peptide variant or wild-type
ST peptide were annealed and cloned into the MB3976 expression
vector. To create MB3984 (encoding MM-416776 peptide full length
wild-type ST peptide as a prepro protein), containing the amino
acid sequence, NSSNYCCELCCNPACTGCY (SEQ ID NO:26) fused downstream
of the pre-pro sequence, MB 3976 was digested with BsaI/XhoI and
ligated to annealed oligos MO3621
(5'GCATGAATAGTAGCAATTACTGCTGTGAATTGTGTTGTAATCCTGCTTGTACCGGG- T
GCTATTAATAAC 3' (SEQ ID NO:62)) and MO3622
(5'TCGAGTTATTAATAGCACCCGGTACA- AGCAGGATTACAACACAATTCACAGCAGTA
ATTGCTACTATTC 3' (SEQ ID NO:63)). To create MB3985 (encoding MD-915
as a prepro protein) containing the following amino acid sequence,
NSSNYCCEYCCNPACTGCY (SEQ ID NO:28) fused downstream of the pre-pro
sequence, MB 3976 was digested with BsaI/XhoI and ligated to
annealed oligos M03529
(5'GCATGAATAGTAGCAATTACTGCTGTGAATATTGTTGTAATCCT- GCTTGTACCGGGT
GCTATTAATAAC 3' (SEQ ID NO:64)) and MO3530
(5'TCGAGTTATTAATAGCACCCGGTACAAGCAGGATTACAACAATATTCACAGCAGTA
ATTGCTACTATTC 3' (SEQ ID NO:65)).
[0119] The MD-915 peptide and the MM-416776 peptide were produced
as follows. The expression vectors were transformed into E. coli
bacterial host BL21 .lambda. DE3 (Invitrogen). A single colony was
innoculated and grown shaking overnight at 30.degree. C. in L
broth+25 mg/l kanamycin. The overnight culture was added to 3.2 L
of batch medium (Glucose 25 g/l, Caseamino Acids 5 g/l, Yeast
Extract 5 g/l, KH.sub.2PO.sub.4 13.3 g/l, (NH.sub.4).sub.2HPO.sub.4
4 g/l, MgSO.sub.4-7H.sub.20 1.2 g/l, Citric Acid 1.7 g/l, EDTA 8.4
mg/l, CoCl.sub.2-6H.sub.2O 2.5 mg/l, MnCl.sub.2-4H.sub.2O 15 mg/l,
CuCl.sub.2-4H.sub.20 1.5 mg/l, H.sub.3BO.sub.3 3 mg/l,
Na.sub.2MoO.sub.4-2H.sub.20 2.5 mg/l, Zn Acetate-2H.sub.20 13 mg/l,
Ferric Citrate 100 mg/l, Kanamycin 25 mg/l, Antifoam
DF.sub.20.sub.4 1 ml/l) and fermented using the following process
parameters: pH 6.7--control with base only (28% NH.sub.4OH),
30.degree. C., aeration: 5 liters per minute. After the initial
consumption of batch glucose (based on monitoring dissolved oxygen
(DO) levels), 1.5 L of feed medium (Glucose 700 g/l, Caseamino
Acids 10 g/l, Yeast Extract 10 g/l, MgSO.sub.4-7H.sub.20 4 g/l,
EDTA 13 mg/l, CoCl.sub.2-6H.sub.2O 4 mg/l, MnCl.sub.2-4H.sub.2O
23.5 mg/l, CuCl.sub.2-4H.sub.20 2.5 mg/l, H.sub.3BO.sub.3 5 mg/l,
Na.sub.2MoO.sub.4-2H.sub.20 4 mg/l, Zn Acetate-2H.sub.20 16 mg/l,
Ferric Citrate 40 mg/l, Antifoam DF.sub.20.sub.4 1 ml/l) was added
at a feed rate controlled to maintain 20% DO. IPTG was added to 0.2
mM 2 hours post feed start. The total run time was approximately
40-45 hours (until feed exhaustion).
[0120] Cells were collected by centrifugation at 5,000 g for 10
minutes. The cell pellet was discarded and the supernatant was
passed through a 50 Kd ultrafiltration unit. The 50 Kd filtrate
(0.6 liters) was loaded onto a 110 ml Q-Sepharose fast Flow column
(Amersham Pharmacia, equilibrated with 20 mM Tris-HCl pH 7.5) at a
flow rate of 400 ml/hour. The column was washed with six volumes of
20 mM Tris-HCl pH 7.5 and proteins were eluted with 50 mM acetic
acid collecting 50 ml fractions. Fractions containing ST peptide
variant or wild-type ST peptide were pooled and the solvent was
removed by rotary evaporation. The dried proteins were resuspended
in 10 ml of 8% acetic acid, 0.1% trifluoroacetic acid (TFA) and
loaded onto a Varian Polaris C18-A column (250.times.21.2 mm 10
.mu.m, equilibrated in the same buffer) at a flow rate of 20
ml/min. The column was washed with 100 ml of 8% methanol, 0.1% TFA
and developed with a gradient (300 ml) of 24 to 48% methanol, 0.1%
TFA, collecting 5-ml fractions. Fractions containing peptide were
pooled and the solvent was removed by rotary evaporation. The
peptides were dissolved in 0.1%TFA and lyophilized.
[0121] The MD-915 peptide and MM-416776 peptide fractions were
analyzed by standard LCMS and HPLC. LCMS analysis revealed that
MD-915 is more homogeneous than MM-416776 (see FIG. 1a; note that
MD-915 peptide exhibits fewer peaks (Panel B) than MM-416776 (Panel
A)).
1b: Preparation of Synthetic Variant ST Peptides and Wild-Type ST
Peptide
[0122] Peptides were chemically synthesized by a commercial peptide
synthesis company. Varying yields of peptides were obtained
depending on the efficiency of chemical synthesis. Thus, the four
peptides, in decreasing order of yield were: Cys Cys Glu Tyr Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31; MD-1100), 10-20%
yield; Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ
ID NO:29; MM416774); Asn Ser Ser Asn Tyr Cys Cys Glu Tyr Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:28; MD-915); Asn Ser Ser
Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
(SEQ ID NO:26 MM-416776), <5% yield. Thus the specific amino
acid changes introduced into the peptides can create improved
manufacturing properties.
[0123] FIG. 1b shows the total ion chromatograph profile of
synthetically manufactured MD-1100. FIG. 1c shows the total ion
chromatograph profile of the control blank sample. There is one
major peak present in the MD-1100 sample that is not also present
in the control sample. Quantitative analysis suggests the MD-1100
is >98% pure.
EXAMPLE 2
Activation of the Intestinal GC--C Receptor by a Variant ST Peptide
and ST Peptide
[0124] The ability of MD-915, MM-416776, and MD-1100 to activate
the intestinal GC--C receptor was assessed in an assay employing
the T84 human colon carcinoma cell line (American Type Culture
Collection (Bethesda, Md.). For the assays cells were grown to
confluency in 24-well culture plates with a 1:1 mixture of Ham's
F12 medium and Dulbecco's modified Eagle's medium (DMEM),
supplemented with 5% fetal calf serum and were used at between
passages 54 and 60.
[0125] Briefly, monolayers of T84 cells in 24-well plates were
washed twice with 1 ml/well DMEM, then incubated at 37.degree. C.
for 10 min with 0.45 ml DMEM containing 1 mM isobutylmethylxanthine
(IBMX), a cyclic nucleotide phosphodiesterase inhibitor. Test
peptides (50.mu.l) were then added and incubated for 30 minutes at
37.degree. C. The media was aspirated and the reaction was then
terminated by the addition of ice cold 0.5 ml of 0.1N HCl. The
samples were held on ice for 20 minutes and then evaporated to
dryness using a heat gun or vacuum centrifugation. The dried
samples were resuspended in 0.5 ml of phosphate buffer provided in
the Cayman Chemical Cyclic GMP EIA kit (Cayman Chemical, Ann Arbor,
Mich.). Cyclic GMP was measured by EIA according to procedures
outlined in the Cayman Chemical Cyclic GMP EIA kit.
[0126] FIG. 2 shows the activity of chemically synthesized peptide
variants in this GC--C receptor activity assay. In this assay,
MM-416776 and two different MD-1100 peptides (MD-1100(a) and
MD-1100(b), synthesized by two different methods) had activity
comparable to MM-416776. MD-915 and MM-416776 peptide were
chemically synthesized in a manner identical to that of
MD-1100(b).
EXAMPLE 3
MD-915 and MM-416776 Increase Intestinal Transit in Mice
[0127] In order to determine whether the peptides increase the rate
of gastrointestinal transit, the peptides and controls were tested
using a murine gastrointestinal transit (GIT) assay (Moon et al.
Infection and Immunity 25:127, 1979). In this assay, charcoal,
which can be readily visualized in the gastrointestinal tract is
administered to mice after the administration of a test compound.
The distance traveled by the charcoal is measured and expressed as
a percentage of the total length of the colon.
[0128] Mice were fasted with free access to water for 12 to 16
hours before the treatment with peptide or control buffer. The
peptides were orally administered at 1 .mu.g/kg-1 mg/kg of peptide
in buffer (20 mM Tris pH 7.5) 7 minutes before being given an oral
dose of 5% Activated Carbon (Aldrich 242276-250G). Control mice
were administered buffer only before being given a dose of
Activated Carbon. After 15 minutes, the mice were sacrificed and
their intestines from the stomach to the cecum were dissected. The
total length of the intestine as well as the distance traveled from
the stomach to the charcoal front was measured for each animal and
the results are expressed as the percent of the total length of the
intestine traveled by the charcoal front. All results are reported
as the average of 10 mice.+-.standard deviation. A comparison of
the distance traveled by the charcoal between the mice treated with
peptide versus the mice treated with vehicle alone was performed
using a Student's t test and a statistically significant difference
was considered for P<0.05. P-values are calculated using a
two-sided T-Test assuming unequal variances.
[0129] As can be seen in FIG. 3a, b, wild-type ST peptide
(MM-416776, (Sigma-Aldrich, St Louis, Mo.; 0.1 mg/kg),
synthetically manufactured MD-1100 and Zelnorm.RTM. (0.1 mg/kg), a
drug approved for IBS that is an agonist for the serotonin receptor
5HT4, increase gastrointestinal transit rate in this model. FIG. 4a
shows the result of a study demonstrating that intestinal transit
rate increases with an increasing dosage of either recombinantly
synthesized MM-416776 or MD-915. FIG. 4b shows the results of a
study demonstrating both chemically synthesized MM-416776 or
MD-1100 peptide increase intestinal transit rates more than either
Tris buffer alone or an equivalent dose of Zelnorm.RTM..
[0130] The identical experiment was performed to determine if
MD-1100 is effective in a chronic dosing treatment regimen.
Briefly, 8 week old CD1 female mice are dosed orally once a day for
5 days with either MD-1100 (0.06 mg/kg or 0.25 mg/kg in 20 mM Tris
pH 7.5) or vehicle alone (20 mM Tris pH 7.5). On the 5.sup.th day,
a GIT assay is performed identical to that above except 200 .mu.l
of a 10% charcoal solution is administered. FIG. 4c shows the
results of a study demonstrating both chemically synthesized
MD-1100 or Zelnorm.RTM. are effective in a mouse gastrointestinal
motility assay upon chronic dosing (daily for 5 days). The results
are shown side by side with acute dosing (1 day).
EXAMPLE 4
MD-915 Peptide and MM-416776 Peptide Increase Intestinal Secretion
in Suckling Mice (SuMi Assay)
[0131] MM-416776 peptide and MD-915 were tested for their ability
to increase intestinal secretion using a suckling mouse model of
intestinal secretion. In this model a test compound is administered
to suckling mice that are between 7 and 9 days old. After the mice
are sacrificed, the gastrointestinal tract from the stomach to the
cecum is dissected ("guts"). The remains ("carcass") as well as the
guts are weighed and the ratio of guts to carcass weight is
calculated. If the ratio is above 0.09, one can conclude that the
test compound increases intestinal secretion. FIG. 5a shows a dose
response curve for wild-type ST peptide (MM-416776) in this model.
FIG. 5b shows dose response curve for the MD-1100 peptide in this
model. These data show that wild-type ST peptide (purchased from
TDT, Inc. West Chester, Pa.) and the MD-1100 peptide increase
intestinal secretion. The effect of Zelnorm.RTM. was also studied.
As can be seen from FIG. 5, Zelnorm.RTM. at 0.2 mg/kg does not
increase intestinal secretion in this model. FIG. 6a shows a dose
response curve for the recombinant MM-416776 peptide described
above and the recombinant MD-915 peptide described above. As can be
seen from FIG. 6a, both peptides increase intestinal secretion in
this model. Similarly FIG. 6b shows a dose response curve for
chemically synthesized MD-915, MD-1100 and MM-416776 as well as
wild-type ST peptide (purchased from Sigma-Aldrich, St Louis,
Mo.).
[0132] Colonic Hyperalgesia Animal Models
[0133] Hypersensitivity to colorectal distension is common in
patients with IBS and may be responsible for the major symptom of
pain. Both inflammatory and non-inflammatory animal models of
visceral hyperalgesia to distension have been developed to
investigate the effect of compounds on visceral pain in IBS.
I. Trinitrobenzenesulphonic Acid (TNBS)-Induced Rectal Allodynia
Model
[0134] Male Wistar rats (220-250 g) were premedicated with 0.5
mg/kg of acepromazine injected intraperitoneally (IP) and
anesthetized by intramuscular administration of 100 mg/kg of
ketamine. Pairs of nichrome wire electrodes (60 cm in length and 80
.mu.m in diameter) were implanted in the striated muscle of the
abdomen, 2 cm laterally from the white line. The free ends of
electrodes were exteriorized on the back of the neck and protected
by a plastic tube attached to the skin. Electromyographic (EMG)
recordings were started 5 days after surgery. Electrical activity
of abdominal striated muscle was recorded with an
electroencephalograph machine (Mini VIII, Alvar, Paris, France)
using a short time constant (0.03 sec.) to remove low-frequency
signals (<3 Hz).
[0135] Ten days post surgical implantation,
trinitrobenzenesulphonic acid (TNBS) was administered to induce
rectal inflammation. TNBS (80 mg kg.sup.-1 in 0.3 ml 50% ethanol)
was administered intrarectally through a silicone rubber catheter
introduced at 3 cm from the anus under light diethyl-ether
anesthesia, as described (Morteau et al. 1994 Dig Dis Sci 39:1239).
Following TNBS administration, rats were placed in plastic tunnels
where they were severely limited in mobility for several days
before colorectal distension (CRD). Experimental compound was
administered one hour before CRD which was performed by insertion
into the rectum, at 1 cm of the anus, a 4 cm long balloon made from
a latex condom (Gue et al, 1997 Neurogastroenterol. Motil. 9:271).
The balloon was fixed on a rigid catheter taken from an embolectomy
probe (Fogarty). The catheter attached balloon was fixed at the
base of the tail. The balloon, connected to a barostat, was
inflated progressively by step of 15 mmHg, from 0 to 60 mmHg, each
step of inflation lasting 5 min. Evaluation of rectal sensitivity,
as measured by EMG, was performed before (1-2 days) and 3 days
following rectal instillation of TNBS.
[0136] The number of spike bursts that corresponds to abdominal
contractions was determined per 5 min periods. Statistical analysis
of the number of abdominal contractions and evaluation of the
dose-effects relationships was performed by a one way analysis of
variance (ANOVA) followed by a post-hoc (Student or Dunnett tests)
and regression analysis for ED50 if appropriate.
[0137] FIG. 7 shows the results of experiment in which MD-1100
activity was analyzed in the TNBS colorectal model. Significant
decreases in abdominal response are observed at 0.3 .mu.g/kg and 3
.mu.g/kg MD-1100. These results demonstrate that MD-1100 reduces
pain associated with colorectal distension in this animal
model.
II. Stress-Induced Hyperalgesia Model
[0138] Male Wistar Rats (200-250 g) are surgically implanted with
nichrome wire electrodes as in the TNBS model. Ten days post
surgical implantation, partial restraint stress (PRS), is performed
as described by Williams et al. for two hours (Williams et al. 1988
Gastroenterology 64:611). Briefly, under light anesthesia with
ethyl-ether, the foreshoulders, upper forelimbs and thoracic trunk
are wrapped in a confining harness of paper tape to restrict, but
not prevent body movements. Control sham-stress animals are
anaesthetized but not wrapped. Thirty minutes before the end of the
PRS session, the animals are administered test-compound or vehicle.
Thirty minutes to one hour after PRS completion, the CRD distension
procedure is performed as described above for the TNBS model with
barostat at pressures of 15, 30, 45 and 60 mm Hg. Statistical
analysis on the number of bursts is determined and analyzed as in
the TNBS model above.
[0139] Phenylbenzoguinone-Induced Writhing Model
[0140] The PBQ-induced writhing model can be used to assess pain
control activity of the peptides and GC--C receptor agonists of the
invention. This model is described by Siegmund et al. (1957 Proc.
Soc. Exp. Bio. Med. 95:729-731). Briefly, one hour after oral
dosing with a test compound, e.g., a peptide, morphine or vehicle,
0.02% phenylbenzoquinone (PBQ) solution (12.5 mL/kg) is injected by
intraperitoneal route into the mouse. The number of stretches and
writhings are recorded from the 5.sup.th to the 10.sup.th minute
after PBQ injection, and can also be counted between the 35.sup.th
and 40.sup.th minute and between the 60.sup.th and 65.sup.th minute
to provide a kinetic assessment. The results are expressed as the
number of stretches and writhings (mean.+-.SEM) and the percentage
of variation of the nociceptive threshold calculated from the mean
value of the vehicle-treated group. The statistical significance of
any differences between the treated groups and the control group is
determined by a Dunnett's test using the residual variance after a
one-way analysis of variance (P<0.05) using SigmaStat
Software.
[0141] FIGS. 8a and 8b show the effect of different doses of MD-915
and MD-1100 in the PBQ writhing assay. Indomethacin, an NSAID
(nonsteroidal anti-inflammatory drug) with known pain control
activity, was used as the positive control in the assay.
Significant reductions in writhings were observed for MD-915 (1
mg/kg dose) and MD-1100 (2.5 mg/kg dose) compared to the vehicle
control. Loss of efficacy at the highest dose tested has also been
observed for multiple other compounds (such as 5HT-3 antagonists)
tested in similar assays. The results of this study suggest that
both MD-915 and MD-1100 have antinociceptive effects in this
visceral pain model comparable to the intermediate doses of
indomethacin.
EXAMPLE 5
MD-1100 Kd Determination
[0142] To determine the affinity of MD-1100 for GC--C receptors
found in rat intestinal mucosa, a competition binding assay was
performed using rate intestinal epithelial cells. Epithelial cells
from the small intestine of rats were obtained as described by
Kessler et al. (J. Biol. Chem. 245: 5281-5288 (1970)). Briefly,
animals were sacrificed and their abdominal cavities exposed. The
small intestine was rinsed with 300 ml ice cold saline or PBS. 10
cm of the small intestine measured at 10 cm from the pylorus was
removed and cut into 1 inch segments. Intestinal mucosa was
extruded from the intestine by gentle pressure between a piece of
parafilm and a P-1000 pipette tip. Intestinal epithelial cells were
placed in 2 ml PBS and pipetted up and down with a 5 ml pipette to
make a suspension of cells. Protein concentration in the suspension
was measured using the Bradford method (Anal. Biochem. 72: 248-254
(1976)).
[0143] A competition binding assay was performed based on the
method of Giannella et al. (Am. J. Physiol. 245: G492-G498) between
[.sup.125I] labeled MM-416776 and MD-1100. The assay mixture
contained: 0.5 ml of DME with 20 mM HEPES-KOH pH 7.0, 0.9 mg of the
cell suspension listed above, 21.4 fmol[.sup.125I]-MM-416776 (42.8
pM), and different concentrations of competitor MD-1100 (0.01 to
1000 nM). The mixture was incubated at room temperature for 1 hour,
and the reaction stopped by applying the mixture to GF/B
glass-fiber filters (Whatman). The filters were washed with 5 ml
ice-cold PBS and radioactivity was measured. FIG. 9 shows that the
Kd for MD-1100 in this assay is 4.5 nm. %B/Bo is the percentage of
the ratio of radioactivity trapped in each sample (B) compared to
the radioactivity retained in a control sample with no cold
competitor (Bo). Giannella et al. (Am. J Physiol.245: G492-G498)
observed that the Kd for wild-type ST peptide in this same assay
was.about.13 nm.
EXAMPLE 6
Pharmacokinetic properties of MD-1100
[0144] To study the pharmacokinetics of MD-1100, absorbability
studies in mice were performed by administering MD-1100
intravaneously via tail vein injection or orally by gavage to
8-week-old CD1 mice. Serum was collected from the animals at
various time points and tested for the presence of MD-1100 using a
competitive enzyme-linked immunoabsorbent assay (Oxoid, ST EIA kit,
Cat#TD0700). The assay utilized monoclonal antibodies against ST
peptide (antibodies are provided in the Oxoid kit) and
synthetically manufactured MD-1100. FIG. 10a show absorption data
for intravenously and orally administered MD-1100 as detected by
the ELISA assay. MD-1100 appears to be minimally systemically
absorbed and is <2.2% bioavailable.
[0145] A similar bioavailability study was performed in which LCMS
rather than ELISA was used to detect MD-1100. Initially, serum
samples were extracted from the whole blood of exposed and control
mice, then injected directly (10 mL) onto an in-line solid phase
extraction (SPE) column (Waters Oasis HLB 25 mm column,
2.0.times.15 mm direct connect) without further processing. The
sample on the SPE column was washed with a 5% methanol, 95%
dH.sub.2O solution (2.1 mL/min, 1.0 minute), then loaded onto an
analytical column using a valve switch that places the SPE column
in an inverted flow path onto the analytical column (Waters Xterra
MS C8 5 mm IS column, 2.1.times.20 mm). The sample was eluted from
the analytical column with a reverse phase gradient (Mobile Phase
A: 10 mM ammonium hydroxide in dH.sub.2O, Mobile Phase B: 10 mM
ammonium hydroxide in 80% acetonitrile and 20% methanol; 20% B for
the first 3 minutes then ramping to 95% B over 4 min. and holding
for 2 min., all at a flow rate of 0.4 mL/min.). At 9.1 minutes, the
gradient returns to the initial conditions of 20%B for 1 min.
MD-1100 eluted from the analytical column at 1.45 minutes, and was
detected by triple-quadrapole mass spectrometry (MRM, 764 (+2
charge state)>182 (+1 charge state) Da; cone voltage=30V;
collision=20 eV; parent resolution=2 Da at base peak; daughter
resolution=2 Da at base peak). Instrument response was converted
into concentration units by comparison with a standard curve using
known amounts of chemically synthesized MD-1100 prepared and
injected in mouse serum using the same procedure.
[0146] FIG. 10b shows absorption data for IV and orally
administered MD-1100 as detected by LCMS. In this assay, MD-1100
appears similarly minimally systemically absorbed and is <0.11%
bioavailable.
[0147] Administration of Peptides and GC--C Receptor Agonists
[0148] For treatment of gastrointestinal disorders, the peptides
and agonists of the invention are preferably administered orally,
e.g., as a tablet, gel, paste, slurry, liquid, powder or in some
other form. Orally administered compositions can include binders,
flavoring agents, and humectants. The peptides and agonists can be
co-administered with other agents used to treat gastrointestinal
disorders including but not limited to acid suppressing agents such
as Histamine-2 receptor agonists (H2As) and proton pump inhibitors
(PPIs). The peptides and agonists can also be administered by
rectal suppository. For the treatment of disorders outside the
gastrointestinal tract such as congestive heart failure and benign
prostatic hypertrophy, peptides and agonists are preferably
administered parenterally or orally. The peptides described herein
can be used alone or in combination with other agents. For example,
the peptides can be administered together with an analgesic peptide
or compound. The analgesic peptide or compound can be covalently
attached to a peptide described herein or it can be a separate
agent that is administered together with or sequentially with a
peptide described herein in a combination therapy.
[0149] Combination therapy can be achieved by administering two or
more agents, e.g., a peptide described herein and an analgesic
peptide or compound, each of which is formulated and administered
separately, or by administering two or more agents in a single
formulation. Other combinations are also encompassed by combination
therapy. For example, two agents can be formulated together and
administered in conjunction with a separate formulation containing
a third agent. While the two or more agents in the combination
therapy can be administered simultaneously, they need not be. For
example, administration of a first agent (or combination of agents)
can precede administration of a second agent (or combination of
agents) by minutes, hours, days, or weeks. Thus, the two or more
agents can be administered within minutes of each other or within
1, 2, 3, 6, 9, 12, 15, 18, or 24 hours of each other or within 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14 days of each other or within 2,
3, 4, 5, 6, 7, 8, 9, or 10 weeks of each other. In some cases even
longer intervals are possible. While in many cases it is desirable
that the two or more agents used in a combination therapy be
present in within the patient's body at the same time, this need
not be so.
[0150] Combination therapy can also include two or more
administrations of one or more of the agents used in the
combination. For example, if agent X and agent Y are used in a
combination, one could administer them sequentially in any
combination one or more times, e.g., in the order X--Y--X, X--X--Y,
Y--X--Y, Y--Y--X, X--X--Y--Y, etc.
[0151] The agents, alone or in combination, can be combined with
any pharmaceutically acceptable carrier or medium. Thus, they can
be combined with materials that do not produce an adverse, allergic
or otherwise unwanted reaction when administered to a patient. The
carriers or mediums used can include solvents, dispersants,
coatings, absorption promoting agents, controlled release agents,
etc.
[0152] The agents either in their free form or as a salt can be
combined with a polymer such as polylactic-glycoloic acid (PLGA),
poly-(I)-lactic-glycolic-tartaric acid (P(I)LGT) (WO 01/12233),
polyglycolic acid (U.S. Pat. No. 3,773,919), polylactic acid (U.S.
Pat. No. 4,767,628); poly(.epsilon.-caprolactone) to create a
sustained release formulation. Such formulations can be used to
implants that release a peptide or another agent over a period of a
few days, a few weeks or several months depending on the polymer,
the particle size of the polymer, and the size of the implant (see,
e.g., U.S. Pat. No. 6,620,422). Other sustained release
formulations are described in EP 0 467 389 A2, WO 93/241150, U.S.
Pat. No. 5,612,052; WO 97/40085, WO 94/155587, U.S. Pat. No.
5,672,659, U.S. Pat. No. 5,893,985, U.S. Pat. No. 5,134,122, U.S.
Pat. No. 5,192,741, U.S. Pat. No. 5,192,741, and U.S. Pat. No.
5,445,832. In such sustained release formulations microparticles of
peptide are combined with microparticles of polymer. One or more
sustained release implants can be placed in the large intestine,
the small intestine or both.
[0153] The agents can be administered, e.g., by intravenous
injection, intramuscular injection, subcutaneous injection, or by
other routes. The agents can be administered orally, e.g., as a
tablet, gel, paste, slurry, liquid, powder or in some other form.
Orally administered compositions can include binders, flavoring
agents, and humectants. The agents can be included in dentifrices
or oral washes. Thus, oral formulations can include abrasives and
foaming agents. The agents can also be administered transdermally
or in the form a suppository.
[0154] The agents can be a free acid or base, or a
pharmacologically acceptable salt thereof. Solids can be dissolved
or dispersed immediately prior to administration or earlier. In
some circumstances the preparations include a preservative to
prevent the growth of microorganisms. The pharmaceutical forms
suitable for injection can include sterile aqueous or organic
solutions or dispersions which include, e.g., water, an alcohol, an
organic solvent, an oil or other solvent or dispersant (e.g.,
glycerol, propylene glycol, polyethylene glycol, and vegetable
oils). Pharmaceutical agents can be sterilized by filter
sterilization or by other suitable means.
[0155] Suitable pharmaceutical compositions in accordance with the
invention will generally include an amount of the active
compound(s) with an acceptable pharmaceutical diluent or excipient,
such as a sterile aqueous solution, to give a range of final
concentrations, depending on the intended use. The techniques of
preparation are generally well known in the art, as exemplified by
Remington's Pharmaceutical Sciences (18th Edition, Mack Publishing
Company, 1995).
[0156] The agents described herein and combination therapy agents
can be packaged as a kit that includes single or multiple doses of
two or more agents, each packaged or formulated individually, or
single or multiple doses of two or more agents packaged or
formulated in combination. Thus, one or more agents can be present
in first container, and the kit can optionally include one or more
agents in a second container. The container or containers are
placed within a package, and the package can optionally include
administration or dosage instructions. A kit can include additional
components such as syringes or other means for administering the
agents as well as diluents or other means for formulation.
[0157] Analgesic Agents
[0158] The peptides described herein can be used in combination
therapy with an analgesic agent, e.g., an analgesic compound or an
analgesic peptide. The analgesic agent can optionally be covalently
attached to a peptide described herein. Among the useful analgesic
agents are: Ca channel blockers, 5HT receptor antagonists (for
example 5HT3, 5HT4 and 5HT1 receptor antagonists), opioid receptor
agonists (loperamide, fedotozine, and fentanyl), NK1 receptor
antagonists, CCK receptor agonists (e.g., loxiglumide), NK1
receptor antagonists, NK3 receptor antagonists,
norepinephrine-serotonin reuptake inhibitors (NSRI), vanilloid and
cannabanoid receptor agonists, and sialorphin. Analgesics agents in
the various classes are described in the literature.
[0159] Among the useful analgesic peptides are sialorphin-related
peptides, including those comprising the amino acid sequence QHNPR
(SEQ ID NO:111), including: VQHNPR (SEQ ID NO:112); VRQHNPR (SEQ ID
NO:113); VRGQHNPR (SEQ ID NO:114); VRGPQHNPR (SEQ ID NO:115);
VRGPRQHNPR (SEQ ID NO:116); VRGPRRQHNPR (SEQ ID NO:117); and RQHNPR
(SEQ ID NO:118). Sialorphin-related peptides bind to neprilysin and
inhibit neprilysin-mediated breakdown of substance P and
Met-enkephalin. Thus, compounds or peptides that are inhibitors of
neprilysin are useful analgesic agents which can be administered
with the peptides of the invention in a co-therapy or linked to the
peptides of the invention, e.g., by a covalent bond. Sialophin and
related peptides are described in U.S. Pat. No. 6,589,750; U.S.
20030078200 A1; and WO 02/051435 A2.
[0160] Opioid receptor antagonists and agonists can be administered
with the peptides of the invention in co-therapy or linked to the
peptide of the invention, e.g., by a covalent bond. For example,
opioid receptor antagonists such as naloxone, naltrexone, methyl
nalozone, nalmefene, cypridime, beta funaltrexamine, naloxonazine,
naltrindole, and nor-binaltorphimine are thought to be useful in
the treatment of IBS. It can be useful to formulate opioid
antagonists of this type is a delayed and sustained release
formulation such that initial release of the antagonist is in the
mid to distal small intestine and/or ascending colon. Such
antagonists are described in WO 01/32180 A2. Enkephalin
pentapeptide (HOE825; Tyr-D-Lys-Gly-Phe-L-homoserine) is an agonist
of the mu and delta opioid receptors and is thought to be useful
for increasing intestinal motility (Eur. J Pharm. 219:445, 1992),
and this peptide can be used in conjunction with the peptides of
the invention. Also useful is trimebutine which is thought to bind
to mu/delta/kappa opioid receptors and activate release of motilin
and modulate the release of gastrin, vasoactive intestinal peptide,
gastrin and glucagons. Kappa opioid receptor agonists such as
fedotozine, ketocyclazocine, and compounds described in WO
03/097051 A2 can be used with or linked to the peptides of the
invention. In addition, mu opioid receptor agonists such as
morphine, diphenyloxylate, frakefamide
(H-Tyr-D-Ala-Phe(F)-Phe-NH.sub.- 2; WO 01/019849 A1) and loperamide
can be used.
[0161] Tyr-Arg (kyotorphin) is a dipeptide that acts by stimulating
the release of met-enkephalins to elicit an analgesic effect (J.
Biol. Chem 262:8165, 1987). Kyotorphin can be used with or linked
to the peptides of the invention.
[0162] CCK receptor agonists such as caerulein from amphibians and
other species are useful analgesic agents that can be used with or
linked to the peptides of the invention.
[0163] Conotoxin peptides represent a large class of analgesic
peptides that act at voltage gated Ca channels, NMDA receptors or
nicotinic receptors. These peptides can be used with or linked to
the peptides of the invention.
[0164] Peptide analogs of thymulin (FR Application 2830451) can
have analgesic activity and can be used with or linked to the
peptides of the invention.
[0165] CCK (CCKa or CCKb) receptor antagonists, including
loxiglumide and dexloxiglumide (the R-isomer of loxiglumide) (WO
88/05774) can have analgesic activity and can be used with or
linked to the peptides of the invention.
[0166] Other useful analgesic agents include 5-HT4 agonists such as
tegaserod/zelnorm and lirexapride. Such agonists are described in:
EP1321142 A1, WO 03/053432A1, EP 505322 A1, EP 505322 B1, U.S. Pat.
No. 5,510,353, EP 507672 A1, EP 507672 B1, and U.S. P
5,273,983.
[0167] Calcium channel blockers such as ziconotide and related
compounds described in, for example, EP625162B1, U.S. Pat. No.
5,364,842, U.S. Pat. No. 5,587,454, U.S. Pat 5,824,645, U.S. Pat.
No. 5,859,186, U.S. Pat. No. 5,994,305, U.S. Pat. No. 6,087,091,
U.S. Pat. No. 6,136,786, WO 93/13128 A1, EP 1336409 A1, EP 835126
A1, EP 835126 B1, U.S. Pat. No. 5,795,864, U.S. Pat. No. 5,891,849,
U.S. Pat. No. 6,054,429, WO 97/01351 A1, can be used with or linked
to the peptides of the invention.
[0168] Various antagonists of the NK-1, NK-2, and NK-3 receptors
(for a review see Giardina et al. 2003 Drugs 6:758) can be can be
used with or linked to the peptides of the invention.
[0169] NK1 receptor antagonists such as: aprepitant (Merck & Co
Inc), vofopitant, ezlopitant (Pfizer, Inc.), R-673 (Hoffmann-La
Roche Ltd), SR-14033 and related compounds described in, for
example, EP 873753 A1, US 20010006972 A1, US 20030109417 A1, WO
01/52844 A1, can be used with or linked to the peptides of the
invention.
[0170] NK-2 receptor antagonists such as nepadutant (Menarini
Ricerche SpA), saredutant (Sanofi-Synthelabo), SR-144190
(Sanofi-Synthelabo) and UK-290795 (Pfizer Inc) can be used with or
linked to the peptides of the invention.
[0171] NK3 receptor antagonists such as osanetant
(Sanofi-Synthelabo), talnetant and related compounds described in,
for example, WO 02/094187 A2, EP 876347 A1, WO 97/21680 A1, U.S.
Pat. No. 6,277,862, WO 98/11090, WO 95/28418, WO 97/19927, and
Boden et al. (J Med Chem. 39:1664-75, 1996) can be used with or
linked to the peptides of the invention.
[0172] Norepinephrine-serotonin reuptake inhibitors such as
milnacipran and related compounds described in WO 03/077897 A1 can
be used with or linked to the peptides of the invention.
[0173] Vanilloid receptor antagonists such as arvanil and related
compounds described in WO 01/64212 A1 can be used with or linked to
the peptides of the invention.
[0174] Where the analgesic is a peptide and is covalently linked to
a peptide described herein the resulting peptide may also include
at least one trypsin or chymotrypsin cleavage site. When present
within the peptide, the analgesic peptide may be preceded by (if it
is at the carboxy terminus) or followed by (if it is at the amino
terminus) a chymotrypsin or trypsin cleavage site that allows
release of the analgesic peptide.
[0175] In addition to sialorphin-related peptides, analgesic
peptides include: AspPhe, endomorphin-1, endomorphin-2, nocistatin,
dalargin, lupron, zicnotide, and substance P.
[0176] Methods of Treatment
[0177] The peptides of the invention can be used for the treatment
or prevention of cancer, pre-cancerous growths, or metastatic
growths. For example, they can be used for the prevention or
treatment of: colorectal/local metastasized colorectal cancer,
gastrointestinal tract cancer, lung cancer, cancer or pre-cancerous
growths or metastatic growths of epithelial cells, polyps, breast,
colorectal, lung, ovarian, pancreatic, prostatic, renal, stomach,
bladder, liver, esophageal and testicular carcinoma, carcinoma
(e.g., basal cell, basosquamous, Brown-Pearce, ductal carcinoma,
Ehrlich tumor, Krebs, Merkel cell, small or non-small cell lung,
oat cell, papillary, bronchiolar, squamous cell, transitional cell,
Walker), leukemia (e.g., B-cell, T-cell, HTLV, acute or chronic
lymphocytic, mast cell, myeloid), histiocytonia, histiocytosis,
Hodgkin's disease, non-Hodgkin's lymphoma, plasmacytoma,
reticuloendotheliosis, adenoma, adeno-carcinoma, adenofibroma,
adenolymphoma, ameloblastoma, angiokeratoma, angiolymphoid
hyperplasia with eosinophilia, sclerosing angioma, angiomatosis,
apudoma, branchionia, malignant carcinoid syndrome, carcinoid heart
disease, carcinosarcoma, cementoma, cholangioma, cholesteatoma,
chondrosarcoma, chondroblastoma, chondrosarcoma, chordoma,
choristoma, craniopharyngioma, chrondroma, cylindroma,
cystadenocarcinoma, cystadenoma, cystosarconia phyllodes,
dysgenninoma, ependymoma, Ewing sarcoma, fibroma, fibrosarcoma,
giant cell tumor, ganglioneuroma, glioblastoma, glomangioma,
granulosa cell tumor, gynandroblastoma, hamartoma,
hemangioendothelioma, hemangioma, hemangio-pericytoma,
hemangiosarcoma, hepatoma, islet cell tumor, Kaposi sarcoma,
leiomyoma, leiomyosarcoma, leukosarcoma, Leydig cell tumor, lipoma,
liposarcoma, lymphaugioma, lymphangiomyoma, lymphangiosarcoma,
medulloblastoma, meningioma, mesenchymoma, mesonephroma,
mesothelioma, myoblastoma, myoma, myosarcoma, myxoma, myxosarcoma,
neurilemmoma, neuroma, neuroblastoma, neuroepithelioma,
neurofibroma, neurofibromatosis, odontoma, osteoma, osteosarcoma,
papilloma, paraganglioma, paraganglionia. nonchroinaffin,
pinealoma, rhabdomyoma, rhabdomyosarcoma, Sertoli cell tumor,
teratoma, theca cell tumor, and other diseases in which cells have
become dysplastic, immortalized, or transformed.
[0178] The peptides of the invention can be used for the treatment
or prevention of: Familial Adenomatous Polyposis (FAP) (autosomal
dominant syndrome) that precedes colon cancer, hereditary
nonpolyposis colorectal cancer (HNPCC), and inherited autosomal
dominant syndrome.
[0179] For treatment or prevention of cancer, pre-cancerous growths
and metastatic growths, the peptides can be used in combination
therapy with radiation or chemotherapeutic agents, an inhibitor of
a cGMP-dependent phosphodiesterase or a selective cyclooxygenase-2
inhibitor (a number of selective cyclooxygenase-2 inhibitors are
described in WO02062369, hereby incorporated by reference).
[0180] The peptides can be for treatment or prevention of
inflammation. Thus, they can be used alone or in combination with
inhibitor of cGMP-dependent phosphodiesterase or a selective
cyclooxygenase-2 inhibitor for treatment of: organ inflammation,
IBD (e.g, Crohn's disease, ulcerative colitis), asthma, nephritis,
hepatitis, pancreatitis, bronchitis, cystic fibrosis, ischemic
bowel diseases, intestinal inflammations/allergies, coeliac
disease, proctitis, eosnophilic gastroenteritis, mastocytosis, and
other inflammatory disorders.
[0181] The peptides can also be used to treat or prevent
insulin-related disorders, for example: II diabetes mellitus,
hyperglycemia, obesity, disorders associated with disturbances in
glucose or electrolyte transport and insulin secretion in cells, or
endocrine disorders. They can be also used in insulin resistance
treatment and post-surgical and non-post surgery decrease in
insulin responsiveness.
[0182] The peptides can be used to prevent or treat respiratory
disorders, including, inhalation, ventilation and mucus secretion
disorders, pulmonary hypertension, chronic obstruction of vessels
and airways, and irreversible obstructions of vessels and
bronchi.
[0183] The peptides can be used in combination therapy with a
phosphodiesterase inhibitor (examples of such inhibitors can be
found in U.S. Pat. No. 6,333,354, hereby incorporated by
reference).
[0184] The peptides can also be used to prevent or treat:
retinopathy, nephropathy, diabetic angiopathy, and edema
formation
[0185] The peptides can also be used to prevent or treat
neurological disorders, for example, headache, anxiety, movement
disorders, aggression, psychosis, seizures, panic attacks,
hysteria, sleep disorders, depression, schizoaffective disorders,
sleep apnea, attention deficit syndromes, memory loss, and
narcolepsy. They may also be used as a sedative.
[0186] The peptides and detectabley labeled peptides can be used as
markers to identify, detect, stage, or diagnosis diseases and
conditions of the small intestine, including: Crohn's disease,
colitis, inflammatory bowel disease, tumors, benign tumors, such as
benign stromal tumors, adenoma, angioma, adenomatous (pedunculated
and sessile) polyps, malignant, carcinoid tumors, endocrine cell
tumors, lymphoma, adenocarcinoma, foregut, midgut, and hindgut
carcinoma, gastroinstestinal stromal tumor (GIST), such as
leiomyoma, cellular leiomyoma, leiomyoblastoma, and leiomyosarcoma,
gastrointestinal autonomic nerve tumor, malabsorption syndromes,
celiac diseases, diverticulosis, Meckel's diverticulum, colonic
diverticula, megacolon, Hirschsprung's disease, irritable bowel
syndrome, mesenteric ischemia, ischemic colitis, colorectal cancer,
colonic polyposis, polyp syndrome, intestinal adenocarcinoma,
Liddle syndrome, Brody myopathy, infantile convulsions, and
choreoathetosis
[0187] The peptides can be conjugated to another molecule (e.g, a
diagnostic or therapeutic molecule) to target cells bearing the GCC
receptor, e.g., cystic fibrosis lesions and specific cells lining
the intestinal tract. Thus, they can be used to target radioactive
moieties or therapeutic moieties to the intestine to aid in imaging
and diagnosing or treating colorectal/metastasized or local
colorectal cancer and to deliver normal copies of the p53 tumor
suppressor gene to the intestinal tract.
[0188] The peptides can be used alone or in combination therapy to
treat erectile dysfunction.
[0189] The peptides can be used alone or in combination therapy to
treat inner ear disorders, e.g., to treat Meniere's disease,
including symptoms of the disease such as vertigo, hearing loss,
tinnitus, sensation of fullness in the ear, and to maintain fluid
homeostasis in the inner ear.
[0190] The peptides can be used alone or in combination therapy to
treat disorders associated with fluid and sodium retention, e.g.,
diseases of the electrolyte-water/electrolyte transport system
within the kidney, gut and urogenital system, congestive heart
failure, hypertension,
Sequence CWU 1
1
124 1 19 PRT Escherichia coli 1 Asn Ser Ser Asn Tyr Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 2 18 PRT
Escherichia coli 2 Asn Thr Phe Tyr Cys Cys Glu Leu Cys Cys Asn Pro
Ala Cys Ala Gly 1 5 10 15 Cys Tyr 3 18 PRT Escherichia coli 3 Asn
Thr Phe Tyr Cys Cys Glu Leu Cys Cys Tyr Pro Ala Cys Ala Gly 1 5 10
15 Cys Asn 4 18 PRT Citrobacter freundii 4 Asn Thr Phe Tyr Cys Cys
Glu Leu Cys Cys Asn Pro Ala Cys Ala Gly 1 5 10 15 Cys Tyr 5 30 PRT
Yersinia enterocolitica 5 Gln Ala Cys Asp Pro Pro Ser Pro Pro Ala
Glu Val Ser Ser Asp Trp 1 5 10 15 Asp Cys Cys Asp Val Cys Cys Asn
Pro Ala Cys Ala Gly Cys 20 25 30 6 30 PRT Yersinia enterocolitica 6
Lys Ala Cys Asp Thr Gln Thr Pro Ser Pro Ser Glu Glu Asn Asp Asp 1 5
10 15 Trp Cys Cys Glu Val Cys Cys Asn Pro Ala Cys Ala Gly Cys 20 25
30 7 53 PRT Yersinia enterocolitica 7 Gln Glu Thr Ala Ser Gly Gln
Val Gly Asp Val Ser Ser Ser Thr Ile 1 5 10 15 Ala Thr Glu Val Ser
Glu Ala Glu Cys Gly Thr Gln Ser Ala Thr Thr 20 25 30 Gln Gly Glu
Asn Asp Trp Asp Trp Cys Cys Glu Leu Cys Cys Asn Pro 35 40 45 Ala
Cys Phe Gly Cys 50 8 16 PRT Yersinia kristensenii 8 Ser Asp Trp Cys
Cys Glu Val Cys Cys Asn Pro Ala Cys Ala Gly Cys 1 5 10 15 9 17 PRT
Vibrio cholerae 9 Ile Asp Cys Cys Glu Ile Cys Cys Asn Pro Ala Cys
Phe Gly Cys Leu 1 5 10 15 Asn 10 17 PRT Vibrio mimicus 10 Ile Asp
Cys Cys Glu Ile Cys Cys Asn Pro Ala Cys Phe Gly Cys Leu 1 5 10 15
Asn 11 18 PRT Escherichia coli 11 Asn Thr Phe Tyr Cys Cys Glu Leu
Cys Cys Asn Pro Ala Cys Ala Pro 1 5 10 15 Cys Tyr 12 13 PRT Vibrio
cholerae 12 Ile Asp Cys Cys Glu Ile Cys Cys Asn Pro Ala Cys Phe 1 5
10 13 14 PRT Vibrio cholerae 13 Ile Asp Cys Cys Glu Ile Cys Cys Asn
Pro Ala Cys Phe Gly 1 5 10 14 17 PRT Vibrio mimicus 14 Ile Asp Cys
Cys Glu Ile Cys Cys Asn Pro Ala Cys Phe Gly Cys Leu 1 5 10 15 Asn
15 17 PRT Vibrio mimicus 15 Ile Asp Arg Cys Glu Ile Cys Cys Asn Pro
Ala Cys Phe Gly Cys Leu 1 5 10 15 Asn 16 16 PRT Yersinia
enterocolitica 16 Asp Trp Asp Cys Cys Asp Val Cys Cys Asn Pro Ala
Cys Ala Gly Cys 1 5 10 15 17 16 PRT Yersinia enterocolitica 17 Asp
Trp Asp Cys Cys Asp Val Cys Cys Asn Pro Ala Cys Ala Gly Cys 1 5 10
15 18 17 PRT Yersinia enterocolitica 18 Asn Asp Asp Trp Cys Cys Glu
Val Cys Cys Asn Pro Ala Cys Ala Gly 1 5 10 15 Cys 19 16 PRT
Yersinia enterocolitica 19 Trp Asp Trp Cys Cys Glu Leu Cys Cys Asn
Pro Ala Cys Phe Gly Cys 1 5 10 15 20 72 PRT Escherichia coli 20 Met
Lys Lys Leu Met Leu Ala Ile Phe Ile Ser Val Leu Ser Phe Pro 1 5 10
15 Ser Phe Ser Gln Ser Thr Glu Ser Leu Asp Ser Ser Lys Glu Lys Ile
20 25 30 Thr Leu Glu Thr Lys Lys Cys Asp Val Val Lys Asn Asn Ser
Glu Lys 35 40 45 Lys Ser Glu Asn Met Asn Asn Thr Phe Tyr Cys Cys
Glu Leu Cys Cys 50 55 60 Asn Pro Ala Cys Ala Gly Cys Tyr 65 70 21
72 PRT Escherichia coli 21 Met Lys Lys Ser Ile Leu Phe Ile Phe Leu
Ser Val Leu Ser Phe Ser 1 5 10 15 Pro Phe Ala Gln Asp Ala Lys Pro
Val Glu Ser Ser Lys Glu Lys Ile 20 25 30 Thr Leu Glu Ser Lys Lys
Cys Asn Ile Ala Lys Lys Ser Asn Lys Ser 35 40 45 Gly Pro Glu Ser
Met Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys Cys 50 55 60 Asn Pro
Ala Cys Thr Gly Cys Tyr 65 70 22 71 PRT Yersinia enterocolitica 22
Met Lys Lys Ile Val Phe Val Leu Val Leu Met Leu Ser Ser Phe Gly 1 5
10 15 Ala Phe Gly Gln Glu Thr Val Ser Gly Gln Phe Ser Asp Ala Leu
Ser 20 25 30 Thr Pro Ile Thr Ala Glu Val Tyr Lys Gln Ala Cys Asp
Pro Pro Leu 35 40 45 Pro Pro Ala Glu Val Ser Ser Asp Trp Asp Cys
Cys Asp Val Cys Cys 50 55 60 Asn Pro Ala Cys Ala Gly Cys 65 70 23
54 PRT Artificial Sequence Synthetically generated amino terminal
leader sequence 23 Met Lys Lys Ser Ile Leu Phe Ile Phe Leu Ser Val
Leu Ser Phe Ser 1 5 10 15 Pro Phe Ala Gln Asp Ala Lys Pro Val Glu
Ser Ser Lys Glu Lys Ile 20 25 30 Thr Leu Glu Ser Lys Lys Cys Asn
Ile Ala Lys Lys Ser Asn Lys Ser 35 40 45 Gly Pro Glu Ser Met Asn 50
24 53 PRT Artificial Sequence Synthetically generated peptide 24
Met Lys Lys Ser Ile Leu Phe Ile Phe Leu Ser Val Leu Ser Phe Ser 1 5
10 15 Pro Phe Ala Gln Asp Ala Lys Pro Ala Gly Ser Ser Lys Glu Lys
Ile 20 25 30 Thr Leu Glu Ser Lys Lys Cys Asn Ile Val Lys Lys Ser
Asn Lys Ser 35 40 45 Gly Pro Glu Ser Met 50 25 53 PRT Escherichia
coli 25 Met Lys Lys Ser Ile Leu Phe Ile Phe Leu Ser Val Leu Ser Phe
Ser 1 5 10 15 Pro Phe Ala Gln Asp Ala Lys Pro Ala Gly Ser Ser Lys
Glu Lys Ile 20 25 30 Thr Leu Glu Ser Lys Lys Cys Asn Ile Val Lys
Lys Asn Asn Glu Ser 35 40 45 Ser Pro Glu Ser Met 50 26 19 PRT
Artificial Sequence Syntheticaly generated peptide 26 Asn Ser Ser
Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly
Cys Tyr 27 19 PRT Artificial Sequence Syntheticaly generated
peptide 27 Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala
Cys Trp 1 5 10 15 Gly Cys Tyr 28 19 PRT Artificial Sequence
Syntheticaly generated peptide 28 Asn Ser Ser Asn Tyr Cys Cys Glu
Tyr Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 29 14 PRT
Artificial Sequence Syntheticaly generated peptide 29 Cys Cys Glu
Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 30 14 PRT
Artificial Sequence Syntheticaly generated peptide 30 Cys Cys Glu
Leu Cys Cys Asn Pro Ala Cys Trp Gly Cys Tyr 1 5 10 31 14 PRT
Artificial Sequence Syntheticaly generated peptide 31 Cys Cys Glu
Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 32 15 PRT
Artificial Sequence Syntheticaly generated peptide 32 Asn Cys Cys
Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 15 33 15 PRT
Artificial Sequence Syntheticaly generated peptide 33 Asn Cys Cys
Glu Leu Cys Cys Asn Pro Ala Cys Trp Gly Cys Tyr 1 5 10 15 34 15 PRT
Artificial Sequence Syntheticaly generated peptide 34 Asn Cys Cys
Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 15 35 15 PRT
Artificial Sequence Syntheticaly generated peptide 35 Asn Cys Cys
Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 15 36 15 PRT
Artificial Sequence Syntheticaly generated peptide 36 Asn Cys Cys
Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 15 37 15 PRT
Artificial Sequence Syntheticaly generated peptide 37 Asn Cys Cys
Glu Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 15 38 15 PRT
Artificial Sequence Syntheticaly generated peptide 38 Asn Cys Cys
Glu Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr 1 5 10 15 39 21 PRT
Artificial Sequence Syntheticaly generated peptide 39 Asn Ser Ser
Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly
Cys Tyr Asp Phe 20 40 21 PRT Artificial Sequence Syntheticaly
generated peptide 40 Asn Ser Ser Asn Tyr Cys Cys Glu Leu Cys Cys
Asn Pro Ala Cys Trp 1 5 10 15 Gly Cys Tyr Asp Phe 20 41 21 PRT
Artificial Sequence Syntheticaly generated peptide 41 Asn Ser Ser
Asn Tyr Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly
Cys Tyr Asp Phe 20 42 21 PRT Artificial Sequence Syntheticaly
generated peptide 42 Asn Ser Ser Asn Tyr Cys Cys Glu Tyr Cys Cys
Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr Asp Phe 20 43 21 PRT
Artificial Sequence Syntheticaly generated peptide 43 Asn Ser Ser
Asn Tyr Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly
Cys Tyr Asp Phe 20 44 21 PRT Artificial Sequence Syntheticaly
generated peptide 44 Asn Ser Ser Asn Tyr Cys Cys Glu Arg Cys Cys
Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr Asp Phe 20 45 21 PRT
Artificial Sequence Syntheticaly generated peptide 45 Asn Ser Ser
Asn Tyr Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly
Cys Tyr Asp Phe 20 46 16 PRT Artificial Sequence Syntheticaly
generated peptide 46 Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr
Gly Cys Tyr Asp Phe 1 5 10 15 47 16 PRT Artificial Sequence
Syntheticaly generated peptide 47 Cys Cys Glu Leu Cys Cys Asn Pro
Ala Cys Trp Gly Cys Tyr Asp Phe 1 5 10 15 48 16 PRT Artificial
Sequence Syntheticaly generated peptide 48 Cys Cys Glu Phe Cys Cys
Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe 1 5 10 15 49 16 PRT
Artificial Sequence Syntheticaly generated peptide 49 Cys Cys Glu
Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe 1 5 10 15 50 16
PRT Artificial Sequence Syntheticaly generated peptide 50 Cys Cys
Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe 1 5 10 15
51 16 PRT Artificial Sequence Syntheticaly generated peptide 51 Cys
Cys Glu Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe 1 5 10
15 52 16 PRT Artificial Sequence Syntheticaly generated peptide 52
Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp Phe 1 5
10 15 53 17 PRT Artificial Sequence Syntheticaly generated peptide
53 Asn Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp
1 5 10 15 Phe 54 17 PRT Artificial Sequence Syntheticaly generated
peptide 54 Asn Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Trp Gly Cys
Tyr Asp 1 5 10 15 Phe 55 17 PRT Artificial Sequence Syntheticaly
generated peptide 55 Asn Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys
Thr Gly Cys Tyr Asp 1 5 10 15 Phe 56 17 PRT Artificial Sequence
Syntheticaly generated peptide 56 Asn Cys Cys Glu Tyr Cys Cys Asn
Pro Ala Cys Thr Gly Cys Tyr Asp 1 5 10 15 Phe 57 17 PRT Artificial
Sequence Syntheticaly generated peptide 57 Asn Cys Cys Glu Trp Cys
Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp 1 5 10 15 Phe 58 17 PRT
Artificial Sequence Syntheticaly generated peptide 58 Asn Cys Cys
Glu Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp 1 5 10 15 Phe
59 17 PRT Artificial Sequence Syntheticaly generated peptide 59 Asn
Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr Asp 1 5 10
15 Phe 60 42 DNA Artificial Sequence Synthetically generated
oligonucleotide 60 cacaccatat gaagaaatca atattattta tttttctttc tg
42 61 46 DNA Artificial Sequence Synthetically generated
oligonucleotide 61 cacacctcga gttaggtctc catgctttca ggaccacttt
tattac 46 62 69 DNA Artificial Sequence Synthetically generated
oligonucleotide 62 gcatgaatag tagcaattac tgctgtgaat tgtgttgtaa
tcctgcttgt accgggtgct 60 attaataac 69 63 69 DNA Artificial Sequence
Synthetically generated oligonucleotide 63 tcgagttatt aatagcaccc
ggtacaagca ggattacaac acaattcaca gcagtaattg 60 ctactattc 69 64 69
DNA Artificial Sequence Synthetically generated oligonucleotide 64
gcatgaatag tagcaattac tgctgtgaat attgttgtaa tcctgcttgt accgggtgct
60 attaataac 69 65 69 DNA Artificial Sequence Synthetically
generated oligonucleotide 65 tcgagttatt aatagcaccc ggtacaagca
ggattacaac aatattcaca gcagtaattg 60 ctactattc 69 66 21 PRT
Artificial Sequence Synthetically generated peptide 66 Xaa Xaa Xaa
Xaa Xaa Cys Cys Glu Xaa Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly
Cys Tyr Xaa Xaa 20 67 19 PRT Artificial Sequence Synthetically
generated peptide 67 Gln Ser Ser Asn Tyr Cys Cys Glu Tyr Cys Cys
Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 68 19 PRT Artificial
Sequence Synthetically generated peptide 68 Asn Thr Ser Asn Tyr Cys
Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 69 19
PRT Artificial Sequence Synthetically generated peptide 69 Asn Leu
Ser Asn Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr 1 5 10 15
Gly Cys Tyr 70 19 PRT Artificial Sequence Synthetically generated
peptide 70 Asn Ile Ser Asn Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala
Cys Thr 1 5 10 15 Gly Cys Tyr 71 19 PRT Artificial Sequence
Synthetically generated peptide 71 Asn Ser Ser Gln Tyr Cys Cys Glu
Tyr Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 72 18 PRT
Artificial Sequence Synthetically generated peptide 72 Ser Ser Asn
Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly 1 5 10 15 Cys
Tyr 73 19 PRT Artificial Sequence Synthetically generated peptide
73 Gln Ser Ser Gln Tyr Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr
1 5 10 15 Gly Cys Tyr 74 18 PRT Artificial Sequence Synthetically
generated peptide 74 Ser Ser Gln Tyr Cys Cys Glu Tyr Cys Cys Asn
Pro Ala Cys Thr Gly 1 5 10 15 Cys Tyr 75 19 PRT Artificial Sequence
Synthetically generated peptide 75 Asn Ser Ser Asn Tyr Cys Cys Glu
Ala Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 76 19 PRT
Artificial Sequence Synthetically generated peptide 76 Asn Ser Ser
Asn Tyr Cys Cys Glu Arg Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly
Cys Tyr 77 19 PRT Artificial Sequence Synthetically generated
peptide 77 Asn Ser Ser Asn Tyr Cys Cys Glu Asn Cys Cys Asn Pro Ala
Cys Thr 1 5 10 15 Gly Cys Tyr 78 19 PRT Artificial Sequence
Synthetically generated peptide 78 Asn Ser Ser Asn Tyr Cys Cys Glu
Asp Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 79 19 PRT
Artificial Sequence Synthetically generated peptide 79 Asn Ser Ser
Asn Tyr Cys Cys Glu Cys Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly
Cys Tyr 80 19 PRT Artificial Sequence Synthetically generated
peptide 80 Asn Ser Ser Asn Tyr Cys Cys Glu Gln Cys Cys Asn Pro Ala
Cys Thr 1 5 10 15 Gly Cys Tyr 81 19 PRT Artificial Sequence
Synthetically generated peptide 81 Asn Ser Ser Asn Tyr Cys Cys Glu
Glu Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 82 19 PRT
Artificial Sequence Synthetically generated peptide 82 Asn Ser Ser
Asn Tyr Cys Cys Glu Gly Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly
Cys Tyr 83 19 PRT Artificial Sequence Synthetically generated
peptide 83 Asn Ser Ser Asn Tyr Cys Cys Glu His Cys Cys Asn Pro Ala
Cys Thr 1 5 10 15 Gly Cys Tyr 84 19 PRT Artificial Sequence
Synthetically generated peptide 84 Asn Ser Ser Asn Tyr Cys Cys Glu
Ile Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 85 19 PRT
Artificial Sequence
Synthetically generated peptide 85 Asn Ser Ser Asn Tyr Cys Cys Glu
Lys Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 86 19 PRT
Artificial Sequence Synthetically generated peptide 86 Asn Ser Ser
Asn Tyr Cys Cys Glu Met Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly
Cys Tyr 87 19 PRT Artificial Sequence Synthetically generated
peptide 87 Asn Ser Ser Asn Tyr Cys Cys Glu Phe Cys Cys Asn Pro Ala
Cys Thr 1 5 10 15 Gly Cys Tyr 88 19 PRT Artificial Sequence
Synthetically generated peptide 88 Asn Ser Ser Asn Tyr Cys Cys Glu
Pro Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 89 19 PRT
Artificial Sequence Synthetically generated peptide 89 Asn Ser Ser
Asn Tyr Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly
Cys Tyr 90 19 PRT Artificial Sequence Synthetically generated
peptide 90 Asn Ser Ser Asn Tyr Cys Cys Glu Thr Cys Cys Asn Pro Ala
Cys Thr 1 5 10 15 Gly Cys Tyr 91 19 PRT Artificial Sequence
Synthetically generated peptide 91 Asn Ser Ser Asn Tyr Cys Cys Glu
Trp Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly Cys Tyr 92 19 PRT
Artificial Sequence Synthetically generated peptide 92 Asn Ser Ser
Asn Tyr Cys Cys Glu Val Cys Cys Asn Pro Ala Cys Thr 1 5 10 15 Gly
Cys Tyr 93 14 PRT Artificial Sequence Synthetically generated
peptide 93 Cys Cys Glu Ala Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 94 14 PRT Artificial Sequence Synthetically generated
peptide 94 Cys Cys Glu Arg Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 95 14 PRT Artificial Sequence Synthetically generated
peptide 95 Cys Cys Glu Asn Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 96 14 PRT Artificial Sequence Synthetically generated
peptide 96 Cys Cys Glu Asp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 97 14 PRT Artificial Sequence Synthetically generated
peptide 97 Cys Cys Glu Cys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 98 14 PRT Artificial Sequence Synthetically generated
peptide 98 Cys Cys Glu Gln Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 99 14 PRT Artificial Sequence Synthetically generated
peptide 99 Cys Cys Glu Glu Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 100 14 PRT Artificial Sequence Synthetically generated
peptide 100 Cys Cys Glu Gly Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 101 14 PRT Artificial Sequence Synthetically generated
peptide 101 Cys Cys Glu His Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 102 14 PRT Artificial Sequence Synthetically generated
peptide 102 Cys Cys Glu Ile Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 103 14 PRT Artificial Sequence Synthetically generated
peptide 103 Cys Cys Glu Lys Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 104 14 PRT Artificial Sequence Synthetically generated
peptide 104 Cys Cys Glu Met Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 105 14 PRT Artificial Sequence Synthetically generated
peptide 105 Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 106 14 PRT Artificial Sequence Synthetically generated
peptide 106 Cys Cys Glu Pro Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 107 14 PRT Artificial Sequence Synthetically generated
peptide 107 Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 108 14 PRT Artificial Sequence Synthetically generated
peptide 108 Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 109 14 PRT Artificial Sequence Synthetically generated
peptide 109 Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 110 14 PRT Artificial Sequence Synthetically generated
peptide 110 Cys Cys Glu Val Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 111 5 PRT Artificial Sequence Synthetically generated
peptide 111 Gln His Asn Pro Arg 1 5 112 6 PRT Artificial Sequence
Synthetically generated peptide 112 Val Gln His Asn Pro Arg 1 5 113
7 PRT Artificial Sequence Synthetically generated peptide 113 Val
Arg Gln His Asn Pro Arg 1 5 114 8 PRT Artificial Sequence
Synthetically generated peptide 114 Val Arg Gly Gln His Asn Pro Arg
1 5 115 9 PRT Artificial Sequence Synthetically generated peptide
115 Val Arg Gly Pro Gln His Asn Pro Arg 1 5 116 10 PRT Artificial
Sequence Synthetically generated peptide 116 Val Arg Gly Pro Arg
Gln His Asn Pro Arg 1 5 10 117 11 PRT Artificial Sequence
Synthetically generated peptide 117 Val Arg Gly Pro Arg Arg Gln His
Asn Pro Arg 1 5 10 118 6 PRT Artificial Sequence Synthetically
generated peptide 118 Arg Gln His Asn Pro Arg 1 5 119 21 PRT
Artificial Sequence Synthetically generated peptide 119 Xaa Xaa Xaa
Xaa Xaa Cys Cys Xaa Xaa Cys Cys Xaa Xaa Xaa Cys Xaa 1 5 10 15 Xaa
Cys Xaa Xaa Xaa 20 120 21 PRT Artificial Sequence Synthetically
generated peptide 120 Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Xaa Cys Cys
Asn Pro Ala Cys Xaa 1 5 10 15 Gly Cys Xaa Xaa Xaa 20 121 5 PRT
Artificial Sequence Synthetically generated peptide 121 Asn Ser Ser
Asn Tyr 1 5 122 30 PRT Yersinia enterocolitica 122 Gln Ala Cys Asp
Pro Pro Leu Pro Pro Ala Glu Val Ser Ser Asp Trp 1 5 10 15 Asp Cys
Cys Asp Val Cys Cys Asn Pro Ala Cys Ala Gly Cys 20 25 30 123 6 PRT
Artificial Sequence Synthetically generated peptide 123 Lys Lys Lys
Lys Lys Lys 1 5 124 7 PRT Artificial Sequence Synthetically
generated peptide 124 Asp Lys Lys Lys Lys Lys Lys 1 5
* * * * *